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PRODUCTION OF STEVIOL GLYCOSIDES IN RECOMBINANT HOSTS
BACKGROUND OF THE INVENTION
Field of the Invention
[0001] This disclosure relates to recombinant production of steviol glycosides and stevioi
glycoside precursors in recombinant hosts. In particular, this disclosure relates to production of
steviol glycosides comprising steviol-1 3-O-glucoside (13-SMG), steviol-1,2-bioside, steviol-1, 3-
bioside, steviol-1 9-O-glucoside (19-SMG), stevioside, 1,3-stevioside, rubusoside, Rebaudioside
A (RebA), Rebaudioside B (RebB), Rebaudioside C (RebC), Rebaudioside D (RebD),
Rebaudioside E (RebE), Rebaudioside F (RebF), Rebaudioside M (RebM), Rebaudioside Q
(RebQ), Rebaudioside I (Rebl), dulcoside A, or isomers thereof in recombinant hosts.
Description of Related Art
[0001] Sweeteners are well known as ingredients used most commonly in the food,
beverage, or confectionary industries. The sweetener can either be incorporated into a final
food product during production or for stand-alone use, when appropriately diluted, as a tabletop
sweetener or an at-home replacement for sugars in baking. Sweeteners include natural
sweeteners such as sucrose, high fructose com syrup, molasses, maple syrup, and honey and
artificial sweeteners such as aspartame, saccharine, and sucralose. Stevia extract is a natural
sweetener that can be isolated and extracted from a perennial shrub, Stevia rebaudiana. Stevia
is commonly grown in South America and Asia for commercial production of stevia extract.
Stevia extract, purified to various degrees, is used commercially as a high intensity sweetener in
foods and in blends or alone as a tabletop sweetener.
[0002] Chemical structures for several steviol glycosides are shown in Figure 1, including
the diterpene steviol and various steviol glycosides. Extracts of the Stevia plant generally
comprise steviol glycosides that contribute to the sweet flavor, although the amount of each
steviol glycoside often varies, inter alia, among different production batches.
[0002] As recovery and purification of steviol glycosides from the Stevia plant have proven
to be labor intensive and inefficient, there remains a need for a recombinant production system
that can accumulate high yields of desired steviol glycosides, such as RebD and RebM. There
also remains a need for improved production of steviol glycosides in recombinant hosts for
commercial uses.
SUMMARY OF THE INVENTION
[0003] it is against the above background that the present invention provides certain
advantages and advancements over the prior art.
[0004] Although this invention disclosed herein is not limited to specific advantages or
functionalities, the invention provides a recombinant host comprising one or more of:
(a) a gene encoding an ent-kaurene oxidase (KO) polypeptide;
(b) a gene encoding a cytochrome P450 reductase (CPR) polypeptide; and/or
(c) a gene encoding an ent-kaurenoic acid hydroxylase (KAH) polypeptide;
wherein at least one of the genes is a recombinant gene; and
wherein the recombinant host is capable of producing a steviol glycoside precursor.
[0005] The invention also provides a recombinant host comprising:
(a) a gene encoding a geranylgeranyl diphosphate synthase (GGPPS) polypeptide;
(b) a gene encoding an ent-copalyl diphosphate synthase (CDPS) polypeptide;
(c) a gene encoding an ent-kaurene synthase (KS) polypeptide
(d) a gene encoding an ent-kaurene oxidase (KO) polypeptide;
(e) a gene encoding a cytochrome P450 reductase (CPR) polypeptide; and
(f) a gene encoding an ent-kaurenoic acid hydroxylase (KAH) polypeptide;
wherein at least one of the genes is a recombinant gene; and
wherein the recombinant host is capable of producing stevioi.
[0006] In one aspect of the recombinant hosts disclosed herein,
(a) the KO polypeptide comprises a KO polypeptide having at least 60% identity to
an amino acid sequence set forth in SEQ D NO:72 or SEQ D NO:75; 65%
identity to an amino acid sequence set forth in SEQ ID NO:54; at least 70%
identity to an amino acid sequence set forth in SED D NO: 70, SEQ ID NO:71 , or
SEQ D NO:79; at least 40% identity to an amino acid sequence set forth in SEQ
ID NO:77; or at least 50% identity to an amino acid sequence set forth in SEQ ID
NO:78;
(b) the CPR polypeptide comprises a CPR polypeptide having at least 70% identity
to an amino acid sequences set forth in SEQ ID NO:69, SEQ ID NO:74, SEQ ID
N0.76, or SEQ ID NO:87; at least 80% identity to an amino acid sequence set
forth in SEQ ID NO;73; at least 85% identity to an amino acid sequence set forth
in SEQ ID NO:22; at least 65% identity to an amino acid sequence set forth in
SEQ ID NO:28; or at least 50% identity to an amino acid sequence set forth in
SEQ ID NO:98; and/or
(c) the KAH polypeptide comprises a KAH polypeptide having at least 40% identity
to an amino acid sequence set forth in SEQ ID NO:82; at least 50% identity to an
amino acid sequence set forth in SEQ ID NO:91; or at least 60% identity to an
amino acid sequence set forth in SEQ ID NO:68.
The invention further provides a recombinant host comprising one or more of:
(a) a gene encoding a KO polypeptide having at least 60% identity to an amino acid
sequence set forth in SEQ ID NO:75;
(b) a gene encoding a KAH polypeptide having at least 40% identity to an amino
acid sequence set forth in SEQ ID NO:82; and/or
(c) a gene encoding a CPR polypeptide having at least 50% identity to an amino
acid sequence set forth in SEQ ID NO:98;
wherein at least one of the genes is a recombinant gene; and
wherein the recombinant host is capable of producing a steviol glycoside precursor.
The invention further provides a recombinant host comprising one or more of:
(a) a gene encoding a KO polypeptide having at least 70% identity to an amino acid
sequence set forth in SEQ ID NO:70;
(b) a gene encoding a KAH polypeptide having at least 40% identity to an amino
acid sequence set forth in SEQ ID NO:82; and/or
(c) a gene encoding a CPR polypeptide having at least 50% identity to an amino
acid sequence set forth in SEQ ID NO:98;
wherein at least one of the genes is a recombinant gene; and
wherein the recombinant host is capable of producing a steviol glycoside precursor.
[0009] In one aspect of the recombinant hosts disclosed herein, the host further comprises
a gene encoding a KO polypeptide having at least 65% identity to an amino acid sequence set
forth in SEQ ID NO:54.
[001 0] In another aspect of the recombinant hosts disclosed herein, the recombinant host
further comprises a gene encoding a KAH polypeptide having at least 60% identity to an amino
acid sequence set forth in SEQ ID NO:68.
[0011] In another aspect of the recombinant hosts disclosed herein, the recombinant host
further comprises a gene encoding a KO polypeptide having at least 70% identity to an amino
acid sequence set forth in SEQ ID NO:79,
[0012] In one aspect of the recombinant hosts disclosed herein, the host further comprises
one or more of:
(a) a gene encoding a geranylgeranyl diphosphate synthase (GGPPS) polypeptide;
(b) a gene encoding an ent-copalyl diphosphate synthase (CDPS) polypeptide;
and/or
(c) a gene encoding an ent-kaurene synthase (KS) polypeptide;
wherein at least one of the genes is a recombinant gene; and
wherein the recombinant host is capable of producing a steviol glycoside precursor.
[0013] In some aspects of the recombinant hosts disclosed herein,
(a) the GGPPS polypeptide comprises a polypeptide having at least 70% identity to
an amino acid sequence set forth in SEQ ID NO:49;
(b) the CDPS polypeptide comprises a polypeptide having at least 70% identity to an
amino acid sequence set forth in SEQ ID NO:37; and/or
(c) the KS polypeptide comprises a polypeptide having at least 40% identity to an
amino acid sequence set forth in SEQ ID NO:6.
[0014] In one aspect of the recombinant hosts disclosed herein, the recombinant host
further comprises a gene encoding an endoplasmic reticulum membrane polypeptide.
[001 5] In another aspect of the recombinant hosts disclosed herein, the endoplasmic
reticulum membrane polypeptide comprises an Inheritance of cortical ER protein 2 (ICE2)
polypeptide having at least 50% identity to the amino acid sequence set forth in SEQ ID
NO:1 14.
[0016] In one aspect of the recombinant host disclosed herein, the KO polypeptide is a
fusion construct.
[0017] In another aspect, the fusion construct comprises a polypeptide having at least 60%
identity to an amino acid sequence set forth in SEQ ID NO:118 or SEQ ID NO:120.
[0018] In another aspect, the fusion construct has at least 50% identity to an amino acid
sequence set forth in SEQ ID NO:100, SEQ ID NO:102, SEQ ID NO:104, SEQ ID NO:106, SEQ
ID NO:108, SEQ ID NO:1 10, or SEQ ID NO:1 12.
[0019] in one aspect of the recombinant hosts disclosed herein, the host further comprises
one or more of:
(a) a gene encoding a UGT85C polypeptide;
(b) a gene encoding a UGT76G polypeptide;
(c) a gene encoding a UGT74G1 polypeptide;
(d) a gene encoding a UGT91 D2 functional homolog polypeptide; and/or
(e) a gene encoding an EUGT11 polypeptide;
wherein at least one of the genes is a recombinant gene; and
wherein the host is capable of producing a stevio! glycoside.
[0020] In some aspects of the recombinant hosts disclosed herein,
(a) the UGT85C2 polypeptide comprises a polypeptide having at least 55% identity
to an amino acid sequence set forth in SEQ ID NO:30;
(b) the UGT76G1 polypeptide comprises a polypeptide having at least 50% identity
to an amino acid sequence set forth in SEQ ID NO:83;
(c) the UGT74G1 polypeptide comprises a polypeptide having at least 55% identity
to an amino acid sequence set forth in SEQ ID NO:29;
(d) the UGT91D2 functional homolog polypeptide comprises a UGT91D2
polypeptide having 90% or greater identity to the amino acid sequence set forth
in SEQ ID NO:84 or a UGT91D2e-b polypeptide having 90% or greater identity to
the amino acid sequence set forth in SEQ ID NO:88; and/or
(e) the EUGT1 1 polypeptide comprises a polypeptide having at least 65% identity to
an amino acid sequence set forth in SEQ ID NO:86.
[0021] In some aspects, the recombinant hosts disclosed herein comprise a plant cell, a
mammalian cell, an insect cell, a fungal cell, or a bacterial cell.
[0022] In one aspect, the bacterial cell comprises Escherichia bacteria cells, for example,
Escherichia coli cells; Lactobacillus bacteria cells; Lactococcus bacteria cells; Cornebacterium
bacteria cells; Acetobacter bacteria cells; Acinetobacter bacteria cells; or Pseudomonas
bacterial cells.
[0023] In one aspect, the fungal cell comprises a yeast cell.
[0024] In one aspect, the yeast cell is a cell from Saccharomyces cerevisiae,
Schizosaccharomyces pombe, Yarrowia lipolytica, Candida glabrata, Ashbya gossypii,
Cyberlindnera jadinii, Pichia pastoris, Kluyveromyces lactis, Hansenula polymorpha, Candida
boidinii, Arxula adeninivorans, Xanthophyllomyces dendrorhous, or Candida albicans species.
[0025] In one aspect, the yeast ceil is a Saccharomycete.
[0026] In one aspect, the yeast cell is a cell from the Saccharomyces cerevisiae species.
[0027] The invention further provides a method of producing a steviol glycoside or a steviol
glycoside precursor, comprising:
(a) growing a recombinant host disclosed herein in a culture medium, under
conditions in which any of the genes disclosed herein are expressed;
wherein the steviol glycoside or the steviol glycoside precursor is synthesized by said
host; and/or
(b) optionally quantifying the steviol glycoside or the steviol glycoside precursor;
and/or
(c) optionally isolating the steviol glycoside or the steviol glycoside precursor.
[0028] n some aspects, the steviol glycoside comprises steviol-1 3-O-glucoside (13-SMG),
steviol-1 ,2-bioside, steviol-1 ,3-bioside, steviol-1 9-Oglucoside (19-SMG), stevioside, 1,3-
stevioside, rubusoside, Rebaudioside A (RebA), Rebaudioside B (RebB), Rebaudioside C
(RebC), Rebaudioside D (RebD), Rebaudioside E (RebE), Rebaudioside F (RebF),
Rebaudioside M (RebM), Rebaudioside Q (RebQ), Rebaudioside I (Rebi), dulcoside A, di-
glycosylated steviol, tri-glycosylated steviol, tetra-glycosylated steviol, penta-glycosylated
steviol, hexa-glycosyiated steviol, hepta-glycosylated steviol, or isomers thereof.
[0029] In some aspects, the steviol glycoside or steviol glycoside precursor produced by the
recombinant hosts or methods disclosed herein accumulates to a detectable concentration
when cultured under said conditions.
[0030] In some aspects, the steviol glycoside or steviol glycoside precursor produced by the
recombinant hosts or methods disclosed herein has an undetectable concentration of stevia
plant-derived contaminants.
[0031] In some aspects, the steviol glycoside or steviol glycoside precursor produced by the
recombinant hosts or methods disclosed herein has a steviol glycoside composition enriched for
RebD or RebM relative to the steviol glycoside composition of a wild-type Stevia plant.
[0032] These and other features and advantages of the present invention will be more fully
understood from the following detailed description taken together with the accompanying claims.
It is noted that the scope of the claims is defined by the recitations therein and not by the
specific discussion of features and advantages set forth in the present description.
BRIEF DESCRIPTION OF THE DRAWINGS
[0033] The following detailed description of the embodiments of the present invention can
be best understood when read in conjunction with the following drawings, where like structure is
indicated with like reference numerals and in which:
[0034] Figure 1 shows a schematic of the engineered biosynthetic pathway for producing
steviol in yeast from geranylgeranyl diphosphate using geranylgeranyl diphosphate synthase
(GGPPS), ent-copalyl diphosphate synthase (CDPS), ent-kaurene synthase (KS), ent-kaurene
oxidase (KO), and ent-kaurenoic acid hydroxylase (KAH) polypeptides.
[0035] Figure 2 shows representative steviol glycoside glycosylation reactions catalyzed by
suitable uridine S'-diphospho (UDP) glycosyi transferases (UGT) enzymes and chemical
structures for several steviol glycoside compounds.
[0036] Figure 3 shows Rebaudioside B (RebB) production in a steviol glycoside-producing
S. cerevisiae strain individually expressing S. rebaudiana K01 (SrKOI) encoded by the
nucleotide sequence set forth in SEQ D NO:59, the KO encoded by the codon-optimized
nucleotide sequence set forth in SEQ D NO:55, or the KO encoded by the nucleotide sequence
set forth in SEQ ID NO:56. RebB production was measured by liquid chromatography-mass
spectrometry (LC-MS) analysis as µΜ/OD600 of individual cultures. See Example 3.
[0037] Figure 4 shows production of ent-kaurenoic acid in steviol glycoside-producing S.
cerevisiae strains individually expressing SrKOI encoded by the nucleotide sequence set forth
in SEQ ID NO:59, the KO encoded by the codon-optimized nucleotide sequence set forth in
SEQ ID NO:55, or the KO encoded by the nucleotide sequence set forth in SEQ ID NO:56, as
measured by LC-MS analysis of culture samples. Ent-kaurenoic acid levels were calculated as
the Area under Curve (AUC) of LC-MS peaks corresponding to ent-kaurenoic acid. See
Example 3.
[0038] Figure 5 shows production of total (extracellular plus intracellular) steviol glycosides
in a steviol glycoside-producing S. cerevisiae strain overexpressing S. rebaudiana KAHel
(SrKAHel; encoded by the nucleotide sequence set forth in SEQ ID NO; 18) or in a steviol
glycoside-producing S. cerevisiae stain co-expressing SrKAHel (encoded by the nucleotide
sequence set forth in SEQ ID NO: 18) and a KO encoded by the nucleotide sequences set forth
in any one of SEQ ID NOs: 55-60, compared to a control strain that does not overexpress
SrKAHel or express a KO encoded by the nucleotide sequence set forth in any one of SEQ ID
NOs: 55-60. Production of total steviol glycosides was quantified by comparision to a standard
curve. Values plotted on the y-axis in µΜ are an average of three biological replicates. See
Example 4.
[0039] Figure 6 shows production of Rebaudioside A (RebA), Rebaudioside D (RebD), and
Rebaudioside M (RebM) in a steviol glycoside-producing S. cerevisiae strain overexpressing
SrKAHel (encoded by the nucleotide sequence set forth in SEQ ID NO:18) and further
expressing either the KO encoded by the nucleotide sequence set forth in SEQ ID NO:56 or the
KO encoded by the nucleotide sequence set forth in SEQ ID NO:65. Production of RebA +
RebD + RebM was measured in µΜ. See Example 4 .
[0040] Figure 7 shows production of glycosylated ent-kaurenoic acid in a steviol glycoside-
producing S. cerevisiae strain overexpressing SrKAHel (encoded by the nucleotide sequence
set forth in SEQ ID NO: 18) or in a steviol glycoside-producing strain coexpressing SrKAHel
(encoded by the nucleotide sequence set forth in SEQ ID NO: 18) and a KO encoded by the
nucleotide sequences set forth in any one of SEQ ID NOs: 55-60). Values were calculated as
the AUC of LC-MS peaks corresponding to glycosylated ent-kaurenoic acid and as an average
of three biological replicates. See Example 4.
[0041] Figure 8 shows production of glycosylated ent-kaurenol in a steviol glycoside-
producing S. cerevisiae strain overexpressing SrKAHel (encoded by the nucleotide sequence
set forth in SEQ ID NO:18) or in a steviol glycoside-producing S. cerevisiae strain co-expressing
SrKAHel (encoded by the nucleotide sequence set forth in SEQ ID NO:18) and a KO encoded
by the nucleotide sequence set forth in SEQ ID NOs: 55-60). Values plotted on the y-axis were
calculated as the AUC of LC-MS peaks corresponding to glycosylated ent-kaurenol. See
Example 4 .
[0042] Figure 9 shows Rebaudioside IVf (RebM) production in a steviol glycoside-producing
S. cerevisiae strain expressing CPR1 (encoded by the codon-optimized nucleotide sequence
set forth in SEQ ID NO:61 ) or CPR7 (encoded by the nucleotide sequence set forth in SEQ ID
NO:23). Values plotted on the y-axis were measured in µΜ. See Example 5.
[0043] Figure 10 shows Rebaudioside M (RebM) production in a steviol glycoside-producing
S. cerevisiae strain overexpressing SrKAHel (encoded by the codon-optimized nucleotide
sequence set forth in SEQ ID NO:18) and further expressing CPR4497 encoded by the
nucleotide sequence set forth in SEQ ID NO;62. Values plotted on the y-axis indicate µΜ
concentration of RebM. See Example 5 .
[0044] Figure 11A shows an LC-MS chromatogram of a steviol-1 3-O-glucoside (13-SMG)
standard. Figure 11B shows production of 13-SMG by a steviol glycoside-producing S.
cerevisiae strain expressing the KAH encoded by the nucleotide sequence set forth in SEQ ID
NO:80 (amino acid sequence set forth in SEQ ID NO:82). See Example 7.
[0045] Figure 12 shows steviol-1 3-O-glucoside (13-SMG) and Rebaudioside B (RebB)
production in a steviol glycoside-producing S. cerevisiae strain co-expressing a KO and a CPR.
The KO was selected from SrKOI (encoded by the codon-optimized nucleotide sequence set
forth in SEQ ID NO:59), the KO encoded by the codon-optimized nucleotide sequence set forth
in SEQ ID NO:63, or the KO encoded by the codon-optimized nucleotide sequence set forth in
SEQ ID NO:64. The cytochrome P450 reductase (CPR) polypeptide was selected from the
CPR encoded by the codon-optimized nucleotide sequence set forth in SEQ ID NO:66 or the
CPR encoded by the codon-optimized nucleotide sequence set forth in SEQ ID NO:67. Values
displayed on the y-axis are µΜ concentrations of the indicated steviol glycosides. See Example
6.
[0046] Figure 13 shows production of steviol-1 3-O-glucoside (13-SMG) and rubusoside in a
steviol glycoside-producing S. cerevisiae strain expressing SrKAHel (encoded by the
nucleotide sequence set forth in SEQ ID NO: 18), the KAH encoded by the nucleotide sequence
set forth in SEQ ID NO:80, or the KAH encoded by the codon-optimized nucleotide sequence
set forth in SEQ ID NO:81 . Values displayed in the y-axis are µΜ concentrations of 13-SMG
and rubusoside, averaged over eight biological replicates and normalized to OD600 measured
using a plate reader. Error bars are ± the respective standard deviation. See Example 7.
[0047] Figure 14 shows cytochrome P450 reductase (CPR) polypeptide activity on
cytochrome c upon incubation with microsomal protein prepared from S. cerevisiae strains
expressing SrKAHel (encoded by the nucleotide sequence set forth in SEQ ID NO:18) alone or
in combination with CPR1 (encoded by the nucleotide sequence set forth in SEQ ID NO:61) or
CPR12 (encoded by the nucleotide sequence set forth in SEQ ID NO:97). Results are shown in
U/mg as an average of two biological replicates. See Example 9.
[0048] Figure 15A shows steviol accumulation upon 30 min incubation of ent-kaurenoic acid
with microsomal protein prepared from S. cerevisiae strains expressing SrKAHel (encoded by
the nucleotide sequence set forth in SEQ ID NO: 18) alone or in combination with CPR1
(encoded by the nucleotide sequence set forth in SEQ ID NO:61) or CPR12 (encoded by the
nucleotide sequence set forth in SEQ ID NO:97). Results are shown in AUC as an average of
three biological replicates. Control reactions comprised the microsomal protein described
above, but these were not incubated for 30 min prior to measurement of steviol accumulation.
Figure 15B shows levels of ent-kaurenoic acid following 30 min incubation of ent-kaurenoic acid
with microsomal protein prepared from S. cerevisiae strains expressing SrKAHel (encoded by
the nucleotide sequence set forth in SEQ ID NO:18) alone or in combination with CPR1
(encoded by the nucleotide sequence set forth in SEQ ID NO:61) or CPR12 (encoded by the
nucleotide sequence set forth in SEQ ID NO:97). Results are shown in µΜ as an average of
three biological replicates. Control reactions comprised the microsomal protein described
above but were not incubated for 30 min prior to measurement of ent-kaurenoic acid levels.
See Example 9.
[0049] Figure 16 shows steviol-13-O-glucoside (13-SMG), 1,2-bioside, Rebaudioside B
(RebB), ent-kaurenoic acid, and ent-kaurene levels accumulated by a steviol glycoside-
producing S. cerevisiae strain expressing SrKOi (SEQ ID NO:59, SEQ ID NO:79), a KO
encoded by the nucleotide sequence set forth in SEQ ID NO:65, or a fusion construct between
either SrKOi or the KO encoded by the nucleotide sequence set forth in SEQ ID NO:65 and the
NADPH-dependent P450 oxidoreductase domain of CYP102A1 (referred to herein as the "BMR
domain"). Figure 16A shows levels of 13-SMG, 1,2-bioside, and RebB measured by LC-MS for
a steviol glycoside-producing S. cerevisiae strain expressing SrKOI (SEQ ID NO:59, SEQ ID
NO:79), a fusion construct of SrKOI and BMR (SEQ ID NO:99, SEQ ID NO:100), a fusion
construct of SrKOI and BMR W 1046A (SEQ ID NO:101, SEQ ID NO:102), a fusion construct of
truncated SrKOI and BMR (SEQ ID NO: 103, SEQ ID NO:104), a fusion construct of truncated
SrKOI and BMR W1046A (SEQ ID ΝΟ .Ί 05, SEQ ID NO:106), or a control plasmid. Figure 16B
shows levels of ent-kaurenoic acid and ent-kaurene measured by LC-UV for a steviol glycoside-
producing S. cerevisiae strain expressing SrKOI (SEQ ID NO:59, SEQ ID NO:79), a fusion
construct of SrKOI and BMR (SEQ ID NO:99, SEQ ID NO: 100), a fusion construct of SrKOI
and BMR W 1046A (SEQ ID NO:101, SEQ ID NO:102), a fusion construct of truncated SrKOI
and BMR (SEQ ID NO:103, SEQ ID NO:104), a fusion construct of truncated SrKOI and BMR
W1046A (SEQ ID NO:105, SEQ ID NO:106), or a control plasmid. Figure 16C shows levels of
13-SMG, 1,2-bioside, and RebB measured by LC-MS for a steviol glycoside-producing S.
cerevisiae strain expressing the KO encoded by the nucleotide sequence set forth in SEQ ID
NO:65, a fusion construct of the KO encoded by the nucleotide sequence set forth in SEQ ID
NO:65 and BMR (SEQ ID NO:107, SEQ ID NO:108), a fusion construct of the KO encoded by
the nucleotide sequence set forth in SEQ ID NO:65 and BMR W1046A (SEQ ID NO: 109, SEQ
ID NO:1 10), a fusion construct of a truncated KO encoded by the nucleotide sequence set forth
in SEQ ID NO:65 and BMR W1046A (SEQ ID NO:1 11, SEQ ID NO:1 12), or a plasmid control.
Figure 16D shows levels of ent-kaurenoic acid or ent-kaurene accumulated by a steviol
glycoside-producing S cerevisiae strain expressing the KO encoded by the nucleotide
sequence set forth in SEQ ID NO:65, a fusion construct of the KO encoded by the nucleotide
sequence set forth in SEQ ID NO:65 and BMR (SEQ ID NO:107, SEQ ID NO:108), a fusion
construct of the KO encoded by the nucleotide sequence set forth in SEQ ID NO:65 and BMR
W1046A (SEQ ID NO:109, SEQ ID NO:1 10), a fusion construct of a truncated KO encoded by
the nucleotide sequence set forth in SEQ ID NO:65 and BMR W1046A (SEQ ID NO:1 11, SEQ
ID NO:1 12), or a plasmid control. See Example 10.
DETAILED DESCRIPTION OF THE INVENTION
[0050] Before describing the present invention in detail, a number of terms will be defined.
As used herein, the singular forms "a," "an," and "the" include plural referents unless the context
clearly dictates otherwise. For example, reference to a "nucleic acid" means one or more
nucleic acids.
[0051] It is noted that terms like "preferably," "commonly," and "typically" are not utilized
herein to limit the scope of the claimed invention or to imply that certain features are critical,
essential, or even important to the structure or function of the claimed invention. Rather, these
terms are merely intended to highlight alternative or additional features that can or cannot be
utilized in a particular embodiment of the present invention.
[0052] For the purposes of describing and defining the present invention it is noted that the
term "substantially" is utilized herein to represent the inherent degree of uncertainty that can be
attributed to any quantitative comparison, value, measurement, or other representation. The
term "substantially" is also utilized herein to represent the degree by which a quantitative
representation can vary from a stated reference without resulting in a change in the basic
function of the subject matter at issue.
[0053] Methods well known to those skilled in the art can be used to construct genetic
expression constructs and recombinant cells according to this invention. These methods include
in vitro recombinant DNA techniques, synthetic techniques, in vivo recombination techniques,
and polymerase chain reaction (PGR) techniques. See, for example, techniques as described in
Green & Sambrook, 2012, MOLECULAR CLONING: A LABORATORY MANUAL, Fourth
Edition, Cold Spring Harbor Laboratory, New York; Ausubei et ai 1989, CURRENT
PROTOCOLS N MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley
Interscience, New York, and PGR Protocols: A Guide to Methods and Applications (Innis et a/.,
1990, Academic Press, San Diego, CA).
[0054] As used herein, the terms "polynucleotide", "nucleotide", "oligonucleotide", and
"nucleic acid" can be used interchangeably to refer to nucleic acid comprising DNA, RNA,
derivatives thereof, or combinations thereof.
[0055] As used herein, the terms "microorganism," "microorganism host," "microorganism
host cell," "recombinant host," and "recombinant host cell" can be used interchangeably. As
used herein, the term "recombinant host" is intended to refer to a host, the genome of which has
been augmented by at ieast one DNA sequence. Such DNA sequences include but are not
limited to genes that are not naturally present, DNA sequences that are not normally transcribed
into RNA or translated into a protein ("expressed"), and other genes or DNA sequences which
one desires to introduce into a host. It will be appreciated that typically the genome of a
recombinant host described herein is augmented through stable introduction of one or more
recombinant genes. Generally, introduced DNA is not originally resident in the host that is the
recipient of the DNA, but it is within the scope of this disclosure to isolate a DNA segment from
a given host, and to subsequently introduce one or more additional copies of that DNA into the
same host, e.g., to enhance production of the product of a gene or alter the expression pattern
of a gene in some instances, the introduced DNA will modify or even replace an endogenous
gene or DNA sequence by, e.g., homologous recombination or site-directed mutagenesis.
Suitable recombinant hosts include microorganisms.
[0056] As used herein, the term "recombinant gene" refers to a gene or DNA sequence that
is introduced into a recipient host, regardless of whether the same or a similar gene or DNA
sequence may already be present in such a host. "Introduced," or "augmented" in this context,
is known in the art to mean introduced or augmented by the hand of man. Thus, a recombinant
gene can be a DNA sequence from another species or can be a DNA sequence that originated
from or is present in the same species but has been incorporated into a host by recombinant
methods to form a recombinant host. It will be appreciated that a recombinant gene that is
introduced into a host can be identical to a DNA sequence that is normally present in the host
being transformed, and is introduced to provide one or more additional copies of the DNA to
thereby permit overexpression or modified expression of the gene product of that DNA. In some
aspects, said recombinant genes are encoded by cDNA. in other embodiments, recombinant
genes are synthetic and/or codon-optimized for expression in S. cerevisiae.
[0057] As used herein, the term "engineered biosynthetic pathway" refers to a biosynthetic
pathway that occurs in a recombinant host, as described herein. In some aspects, one or more
steps of the biosynthetic pathway do not naturally occur in an unmodified host. In some
embodiments, a heterologous version of a gene is introduced into a host that comprises an
endogenous version of the gene.
[0058] As used herein, the term "endogenous" gene refers to a gene that originates from
and is produced or synthesized within a particular organism, tissue, or cell. In some
embodiments, the endogenous gene is a yeast gene. In some embodiments, the gene is
endogenous to S. cerevisiae, including, but not limited to S. cerevisiae strain S288C. In some
embodiments, an endogenous yeast gene is overexpressed. As used herein, the term
"overexpress" is used to refer to the expression of a gene in an organism at levels higher than
the level of gene expression in a wild type organism. See, e.g., Prelich, 2012, Genetics
190:841-54. In some embodiments, an endogenous yeast gene is deleted. See, e.g., Giaever
& Nislow, 2014, Genetics 197(2):451-65. As used herein, the terms "deletion," "deleted,"
"knockout," and "knocked out" can be used interchangabley to refer to an endogenous gene that
has been manipulated to no longer be expressed in an organism, including, but not limited to, S.
cerevisiae.
[0059] As used herein, the terms "heterologous sequence" and "heterologous coding
sequence" are used to describe a sequence derived from a species other than the recombinant
host, in some embodiments, the recombinant host is an S. cerevisiae cell, and a heterologous
sequence is derived from an organism other than S. cerevisiae. A heterologous coding
sequence, for example, can be from a prokaryotic microorganism, a eukaryotic microorganism,
a plant, an animal, an insect, or a fungus different than the recombinant host expressing the
heterologous sequence. In some embodiments, a coding sequence is a sequence that is native
to the host.
[0060] A "selectable marker" can be one of any number of genes that complement host cell
auxotrophy, provide antibiotic resistance, or result in a color change. Linearized DNA fragments
of the gene replacement vector then are introduced into the cells using methods well known in
the art (see below). Integration of the linear fragments into the genome and the disruption of the
gene can be determined based on the selection marker and can be verified by, for example,
PGR or Southern blot analysis. Subsequent to its use in selection, a selectable marker can be
removed from the genome of the host cell by, e.g., Cre-LoxP systems (see, e.g., Gossen et a/.,
2002, Ann. Rev. Genetics 36:153-173 and U.S. 2006/0014264). Alternatively, a gene
replacement vector can be constructed in such a way as to include a portion of the gene to be
disrupted, where the portion is devoid of any endogenous gene promoter sequence and
encodes none, or an inactive fragment of, the coding sequence of the gene.
[0061] As used herein, the terms "variant" and "mutant" are used to describe a protein
sequence that has been modified at one or more amino acids, compared to the wild-type
sequence of a particular protein.
[0062] As used herein, the term "inactive fragment" is a fragment of the gene that encodes a
protein having, e.g., less than about 10% (e.g., less than about 9%, less than about 8%, less
than about 7%, less than about 6%, less than about 5%, less than about 4%, less than about
3%, less than about 2%, less than about 1%, or 0%) of the activity of the protein produced from
the full-length coding sequence of the gene. Such a portion of a gene is inserted in a vector in
such a way that no known promoter sequence is operably linked to the gene sequence, but that
a stop codon and a transcription termination sequence are operably linked to the portion of the
gene sequence. This vector can be subsequently linearized in the portion of the gene sequence
and transformed into a cell. By way of single homologous recombination, this linearized vector
is then integrated in the endogenous counterpart of the gene with inactivation thereof.
[0063] As used herein, the term "stevio! glycoside" refers to Rebaudioside A (RebA) (CAS #
58543-16-1), Rebaudioside B (RebB) (CAS # 58543-17-2), Rebaudioside C (RebC) (CAS #
63550-99-2), Rebaudioside D (RebD) (CAS # 63279-13-0), Rebaudioside E (RebE) (CAS #
63279-14-1), Rebaudioside F (RebF) (CAS # 438045-89-7), Rebaudioside M (RebM) (CAS #
1220616-44-3), Rubusoside (CAS # 63849-39-4), Dulcoside A (CAS # 64432-06-0),
Rebaudioside I (Rebl) (MassBank Record: FU000332), Rebaudioside Q (RebQ), 1,2-Stevioside
(CAS # 57817-89-7), 1,3-Stevioside (RebG), 1,2-bioside (MassBank Record: FU000299), 1,3-
bioside, Stevioi-13-O-glucoside (13-SMG), Steviol-19-O-glucoside (19-SMG), a tri-glucosylated
steviol glycoside, a tetra-glycosylated steviol glycoside, a penta-glucosylated steviol glycoside, a
hexa-glucosylated steviol glycoside, a hepta-glucosyiated steviol glycoside, and isomers
thereof. See Figure 2 ; see also, Steviol Glycosides Chemical and Technical Assessment 69th
JECFA, 2007, prepared by Harriet Wallin, Food Agric. Org.
[0064] As used herein, the terms "steviol glycoside precursor" and "steviol glycoside
precursor compound" are used to refer to intermediate compounds in the steviol glycoside
biosynthetic pathway. Steviol glycoside precursors include, but are not limited to,
geranylgeranyl diphosphate (GGPP), ent-copalyl -diphosphate, ent-kaurene, ent-kaurenol, ent-
kaurenai, ent-kaurenoic acid, and steviol. See Figure 1. In some embodiments, steviol
glycoside precursors are themselves steviol glycoside compounds. For example, 19-SMG,
rubusoside, stevioside, and RebE are steviol glycoside precursors of RebM. See Figure 2 .
Steviol glycosides and/or steviol glycoside precursors can be produced in vivo (i.e., in a
recombinant host), in vitro (i.e., enzymatically), or by whole cell byconversion. As used herein,
the terms "produce" and "accumulate" can be used interchangeably to describe synthesis of
steviol glycosides and steviol glycoside precursors in vivo, in vitro, or by whole cell
bioconversion.
[0065] As used herein, the term "di-glycosylated steviol" can be used to refer to a steviol
molecule comprising two sugar moieties, such as glucose or N-acetylglucosamine (GicNAc).
Non-limiting examples of di-glycosylated steviol molecules include steviol-1 ,3-bioside, steviol-
1,2-bioside, rubusoside, a steviol molecule comprising two glucose moieties, a steviol molecule
comprising one glucose moiety and one GicNAc moiety, and isomers thereof.
[0066] As used herein, the term "tri-glycosylated steviol" can be used to refer to a steviol
molecule comprising three sugar moieties, such as glucose or GicNAc. Non-limiting examples
of tri-glycosy steviol molecules include RebB, RebG, stevioside, a steviol molecule
comprising two glucose moieties and one GlcNAc moiety, and isomers thereof.
[0067] As used herein, the term "tetra- cosy steviol" can be used to refer to a steviol
molecuie comprising four sugar moieties, such as glucose or GlcNAc. Non-limiting examples of
tetra-glycosy steviol molecules include RebA, RebE, RebQ, a steviol molecule comprising
four glucose moieties, a steviol molecule comprising three glucose moieties and one GlcNAc
moiety, and isomers thereof.
[0068] As used herein, the term "penta-glycosy steviol" can be used to refer to a steviol
molecule comprising five sugar moieties, such as glucose or GlcNAc. Non-limiting examples of
penta-glycosy steviol molecules include RebD, a steviol molecule comprising five glucose
moieties, a steviol molecule comprising four glucose moieties and one GlcNAc moiety, and
isomers thereof.
[0069] As used herein, the term "hexa-glycosyiated steviol" can be used to refer to a steviol
molecule comprising six sugar moieties, such as glucose or GlcNAc. Non-limiting examples of
hexa-glycosy steviol molecules include RebM, a steviol molecule comprising six glucose
moieties, a steviol molecule comprising five glucose moieties and one GlcNAc moiety, and
isomers thereof.
[0070] As used herein, the term "hepta-glycosy steviol" can be used to refer to a steviol
molecule comprising seven sugar moieties, such as glucose or GlcNAc. Non-limiting examples
of hepta-glycosy steviol molecules include a steviol molecule comprising seven glucose
moieties and isomers thereof.
[0071] As used herein, the term "glycosy ent-kaurenoic acid" can be used to refer to an
ent-kaurenoic acid molecule comprising sugar moieties, such as glucose or GlcNAc. Non-
limiting examples of glycosy ent-kaurenoic acid molecules include ent-kaurenoic acid
molecule comprising two glucose moieties and one GlcNAc moiety, an ent-kaurenoic acid
molecule comprising three glucose moieties, an ent-kaurenoic acid molecule comprising one
glucose moiety and one GlcNAc moiety, an ent-kaurenoic acid molecule comprising two glucose
moieties, and isomers thereof.
[0072] As used herein, the term "glycosy ent-kaurenol" can be used to refer to an ent-
kaurenol molecule comprising sugar moieties, such as glucose or GlcNAc. Non-limiting
examples of glycosy ent-kaurenol molecules include an ent-kaurenol molecule comprising
three glucose moieties, an ent-kaurenol molecule comprising one glucose moiety and one
GlcNAc moiety, an ent-kaureno! molecule comprising two glucose moieties, and isomers
thereof.
[0073] Recombinant steviol glycoside-producing Saccharomyces cerevisiae (S. cerevisiae)
strains are described in WO 201 1/153378, WO 2013/022989, WO 2014/122227, and W O
2014/122328. Methods of producing steviol glycosides in recombinant hosts, by whole cell bio-
conversion, and in vitro are also described in WO 201 1/153378, WO 2013/022989, W O
2014/122227, and WO 2014/122328.
[0074] In some embodiments, steviol glycosides and/or steviol glycoside precursors are
produced in vivo through expression of one or more enzymes involved in the steviol glycoside
biosynthetic pathway in a recombinant host. For example, a steviol-producing recombinant host
expressing one or more of a gene encoding a GGPPS polypeptide, a gene encoding a CDPS
polypeptide, a gene encoding a KS polypeptide, a gene encoding a KO polypeptide, a gene
encoding a KAH polypeptide, a gene encoding a CPR polypeptide, and a gene encoding a UGT
polypeptide can produce a steviol glycoside and/or steviol glycoside precursors in vivo. See,
e.g., Figures 1 and 2 . The skilled worker will appreciate that one or more of these genes can be
endogenous to the host provided that at least one (and in some embodiments, all) of these
genes is a recombinant gene introduced into the recombinant host.
[0075] in another example, a recombinant host expressing a gene encoding a GGPPS
polypeptide, a gene encoding a CDPS polypeptide, a gene encoding a KS polypeptide, a gene
encoding a KO polypeptide, a gene encoding a KAH polypeptide, and a gene encoding a CPR
polypeptide can produce steviol in vivo. See, e.g., Figures 1. The skilled worker will appreciate
that one or more of these genes can be endogenous to the host provided that at least one (and
in some embodiments, all) of these genes is a recombinant gene introduced into the
recombinant host.
[0076] In another example, a steviol-producing recombinant host expressing a gene
encoding a GGPPS polypeptide, a gene encoding a CDPS polypeptide, a gene encoding a KS
polypeptide, a gene encoding a KO polypeptide, a gene encoding a KAH polypeptide, a gene
encoding a CPR polypeptide, and one or more of a gene encoding a UGT polypeptide can
produce a steviol glycoside in vivo. See, e.g., Figures 1 and 2 . The skilled worker will
appreciate that one or more of these genes can be endogenous to the host provided that at
least one (and in some embodiments, all) of these genes is a recombinant gene introduced into
the recombinant host.
[0077] Non-limiting examples of KS polypeptides are set forth in SEQ ID NOs:1-4 and SEQ
ID NO:6. Non-limiting examples of KO polypeptides are set forth in SEQ D NOs:7-10, 54, 70-
72, 75, and 77-79. Non-limiting examples of KAH polypeptides are set forth in SEQ ID NOs:13-
17, 68, 82, and 91. Non-limiting examples of CPR polypeptides are set forth in SEQ ID NOs:20-
22, 28, 69, 73, 74, 76, 87, and 98. Non-limiting examples of CDPS polypeptides are set forth in
SEQ D NOs:33-39. Non-limiting examples of CDPS-KS polypeptides are set forth in SEQ ID
NOs:40-42. Non-limiting examples of GGPPS polypeptides are set forth in SEQ D NOs:43-50.
[0078] In some embodiments, a recombinant host comprises a nucleic acid encoding a
UGT85C2 polypeptide (SEQ ID NO:32), a nucleic acid encoding a UGT76G1 polypeptide (SEQ
ID NO:83), a nucleic acid encoding a UGT74G1 polypeptide (SEQ ID NO:29), a nucleic acid
encoding a UGT91D2 polypeptide, and/or a nucleic acid encoding a EUGT1 polypeptide (SEQ
ID NO:86). In some aspects, the UGT91D2 polypeptide can be a UGT91D2e polypeptide (SEQ
ID NO:84) or a UGT91D2e-b polypeptide (SEQ ID NO:88). The skilled worker will appreciate
that expression of these genes may be necessary to produce a particular steviol glycoside but
that one or more of these genes can be endogenous to the host provided that at least one (and
in some embodiments, all) of these genes is a recombinant gene introduced into the
recombinant host. In a particular embodiment, a steviol-producing recombinant microorganism
comprises exogenous nucleic acids encoding UGT85C2, UGT76G1, or UGT91D2 polypeptides.
In another particular embodiment, a steviol-producing recombinant microorganism comprises
exogenous nucleic acids encoding UGT85C2, UGT76G1 , UGT74G1 , and UGT91D2
polypeptides. In yet another particular embodiment, a steviol-producing recombinant
microorganism comprises exogenous nucleic acids encoding UGT85C2, UGT76G1, UGT74G1,
and EUGT11 polypeptides. In yet another particular embodiment, a steviol-producing
recombinant microorganism comprises the exogenous nucleic acids encoding UGT85C2,
UGT76G1, UGT74G1, UGT91D2 (including inter alia 91D2e, 91D2m, 91D2e-b, and functional
homologs thereof), and EUGT1 1 polypeptides.
[0079] In certain embodiments, the steviol glycoside is RebA, RebB, RebD, and/or RebM.
RebA can be synthesized in a steviol-producing recombinant microorganism expressing
UGT85C2, UGT76G1, UGT74G1, and UGT91D2. RebB can be synthesized in a steviol-
producing recombinant microorganism expressing UGT85C2, UGT76G1, and UGT9 D2. RebD
can be synthesized in a steviol-producing recombinant microorganism expressing UGT85C2,
UGT76G1 UGT74G1, and UGT91D2 and/or EUGT1 1. RebM can be synthesized in a steviol-
producing recombinant microorganism expressing UGT85C2, UGT76G1 , UGT74G1, and
UGT91 D2 and/or EUGT1 1 (see Figure 2).
[0080] In some embodiments, steviol glycosides and/or steviol glycoside precursors are
produced through contact of a steviol glycoside precursor with one or more enzymes involved in
the steviol glycoside pathway in vitro. For example, contacting steviol with a UGT polypeptide
can result in production of a steviol glycoside in vitro. In some embodiments, a steviol glycoside
precursor is produced through contact of an upstream steviol glycoside precursor with one or
more enzymes involved in the steviol glycoside pathway in vitro. For example, contacting ent-
kaurenoic acid with a KAH enzyme can result in production of steviol in vitro.
[0081] In some embodiments, a steviol glycoside or steviol glycoside precursor is produced
by whole cell bioconversion. For whole cell bioconversion to occur, a host cell expressing one
or more enzymes involved in the steviol glycoside pathway takes up and modifies a stevioi
glycoside precursor in the cell; following modification in vivo, a steviol glycoside remains in the
cell and/or is excreted into the culture medium. For example, a host cell expressing a gene
encoding a UGT polypeptide can take up steviol and glycosylate steviol in the cell; following
glycosylation in vivo, a steviol glycoside can be excreted into the culture medium. In some
embodiments, the cell is permeabilized to take up a substrate to be modified or to excrete a
modified product.
[0082] In some embodiments, stevioi, one or more steviol glycoside precursors, and/or one
or more steviol glycosides are produced by co-culturing of two or more hosts. In some
embodiments, one or more hosts, each expressing one or more enzymes involved in the stevioi
glycoside pathway, produce stevioi, one or more steviol glycoside precursors, and/or one or
more steviol glycosides. For example, a host comprising a GGPPS, a CDPS, a KO, a KS, a
KAH, and/or a CPR and a host comprising one or more UGTs produce one or more stevioi
glycosides.
[0083] In some embodiments, a steviol glycoside or steviol glycoside precursor composition
produced in vivo, in vitro, or by whole cell bioconversion comprises less contaminants than a
stevia extract from, inter alia, a stevia plant. Contaminants include plant-derived compounds
that contribute to off-flavors. Potential contaminants include pigments, lipids, proteins,
phenolics, saccharides, spathulenol and other sesquiterpenes, labdane diterpenes,
monoterpenes, decanoic acid, 8,1 1,14-eicosatrienoic acid, 2-methy!octadecane, pentacosane,
octacosane, tetracosane, octadecanol, stigmasterol, β-sitosterol, a-amyrin, β-amyrin, lupeol, β-
amryin acetate, pentacyclic triterpenes, centauredin, quercitin, epi-alpha-cadinoi, carophyllenes
and derivatives, beta-pinene, beta-sitosterol, and gibberellin.
[0084] As used herein, the terms "detectable amount," "detectable concentration,"
"measurable amount," and "measurable concentration" refer to a level of steviol glycosides
measured in AUC, µΜ/OD600 , mg/L, µΜ, or mM. Steviol glycoside production (i.e., total,
supernatant, and/or intracellular steviol glycoside levels) can be detected and/or analyzed by
techniques generally available to one skilled in the art, for example, but not limited to, liquid
chromatography-mass spectrometry (LC-MS), thin layer chromatography (TLC), high-
performance liquid chromatography (HPLC), ultraviolet-visible spectroscopy/ spectrophotometry
(UV-Vis), mass spectrometry (MS), and nuclear magnetic resonance spectroscopy (NMR).
[0085] As used herein, the term "undetectable concentration" refers to a level of a
compound that is too low to be measured and/or analyzed by techniques such as TLC, HPLC,
UV-Vis, MS, or NMR. In some embodiments, a compound of an "undetectable concentration" is
not present in a steviol glycoside or steviol glycoside precursor composition.
[0086] As used herein, the terms "or" and "and/or" is utilized to describe multiple
components in combination or exclusive of one another. For example, "x, y, and/or z" can refer
to "x" alone, "y" alone, "z" alone, "x, y, and z," "(x and y) or z," "x or (y and z)," or "x or y or z." In
some embodiments, "and/or" is used to refer to the exogenous nucleic acids that a recombinant
cell comprises, wherein a recombinant cell comprises one or more exogenous nucleic acids
selected from a group. In some embodiments, "and/or" is used to refer to production of steviol
glycosides and/or steviol glycoside precursors. In some embodiments, "and/or" is used to refer
to production of steviol glycosides, wherein one or more steviol glycosides are produced. In
some embodiments, "and/or" is used to refer to production of steviol glycosides, wherein one or
more steviol glycosides are produced through one or more of the following steps: culturing a
recombinant microorganism, synthesizing one or more steviol glycosides in a recombinant
microorganism, and/or isolating one or more steviol glycosides.
[0087] In some embodiments, the nucleotide sequence of a nucleic acid encoding a KO
polypeptide is set forth in SEQ ID NO: 55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:58, SEQ
ID NO:59, or SEQ ID NO:60, SEQ ID NO:63, SEQ ID NO:64, or SEQ ID NO:65. In some
aspects, the nucleic acid encoding the KO polypeptide has at least 70% identity to the
nucleotide sequence set forth in SEQ ID NO:55, SEQ ID NO:57, SEQ ID NO:59 or SEQ ID
NO:60, at least 80% identity to the nucleotide sequence set forth in SEQ ID NO:56 or SEQ ID
NO:58, at least 95% identity to the nucleotide sequence set forth in SEQ ID NO:63, or at least
75% identity to the nucleotide sequence set forth in SEQ ID NO:64 or SEQ ID NO:65. In some
embodiments, the amino acid sequence of a KO enzyme is set forth in SEQ ID NO:54, SEQ ID
NO.70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:75, SEQ ID NO:77, SEQ ID NO:78, O R
SEQ ID NO:79. In some embodiments, a host ceil comprises one or more copies of one or
more nucleic acids encoding a KO polypeptide.
[0088] In some embodiments, expression of a KO gene set forth in SEQ ID NO:55 or SEQ
ID NO:56 in a RebB-producing S. cerevisiae strain results in higher production of RebB
compared to expression of SrKOI (SEQ ID NO:59, SEQ ID NO:79) in a RebB-producing S.
cerevisiae strain. See Example 3.
[0089] In some embodiments, expression of a KO gene set forth in SEQ ID NO:55, SEQ ID
NO:56, or SEQ ID NO:57 in an S cerevisiae strain capable of producing RebB with a functional
KO results in production of ent-kaurenoic acid. See Example 3.
[0090] As used herein, the terms "ent-kaurenoic acid hydroxylase" and "steviol synthase"
can be used interchangeably and be abbreviated "KAH." In some embodiments, the nucleotide
sequence of a nucleic acid encoding a KAH enzyme is set forth in SEQ ID NO:18, SEQ ID
NO:80, SEQ ID NO:81, SEQ ID NO:90, or SEQ ID NO:96. In some aspects, the nucleic acid
encoding the KAH polypeptide has at least 75% identity to a nucleotide sequence set forth in
SEQ ID NO:80; or at least 70% identity to a nucleotide sequence set forth in SEQ ID NO:18,
SEQ ID NO:81, SEQ ID NO:90, or SEQ ID NO:96. In some embodiments, the amino acid
sequence of a KAH enzyme is set forth in SEQ ID NO:68, SEQ ID NO:82, or SEQ ID NO:91 . In
some embodiments, a host cell comprises one or more copies of one or more nucleic acids
encoding a KAH enzyme.
[0091] In some embodiments, one or more copies of SrKAHel (SEQ ID NO:18, SEQ ID
NO:68) are expressed in an S cerevisiae strain. For example, in some embodiments, two
copies of SrKAHel (SEQ ID NO: 18, SEQ ID NO:68) are expressed in an S. cerevisiae strain.
[0092] In some embodiments, the nucleotide sequence of a nucleic acid encoding a KAH
enzyme is set forth in SEQ ID NO:80. The nucleic acid of SEQ ID NO:80 encodes a KAH with
an amino acid sequence set forth in SEQ ID NO:82. A version of SEQ ID NO:80 codon-
optimized for expression in S, cerevisiae is set forth in SEQ ID NO:81 . In some embodiments, a
host cell comprises one or more copies of one or more nucleic acids encoding a KAH enzyme.
See Example 7.
[0093] In some embodiments, SrKAHel (SEQ ID NO:18, SEQ ID NO:68) and either the
KAH encoded by the nucleotide sequence set forth in SEQ ID NO:80 or the KAH encoded by
the codon-optimized nucleotide sequence set forth in SEQ ID NO:81 are co-expressed in a
steviol glycoside-producing S. cerevisiae strain. In some embodiments, co-expression of
SrKAHel (SEQ ID NO:18, SEQ ID NO:68) and either the KAH encoded by the nucleotide
sequence set forth in SEQ ID NO:80 or the KAH encoded by the codon-optimized nucleotide
sequence set forth in SEQ ID NO:81 in a steviol glycoside-producing strain results in higher
production of steviol glycosides compared to a control steviol glycoside-producing strain or a
steviol glycoside producing strain overexpressing SrKAHel. See Example 7 and Table 6. In
some aspects, overexpressing SrKAHel results in production of 85.5 µΜ 13-SMG, expression
of SrKAHel and the KAH encoded by the nucleotide set forth in SEQ ID NO:80 results in
production of 153.8 µΜ 13-SMG, and expression of SrKAHel and the KAH encoded by the
nucleotide set forth in SEQ ID NO:81 results in production of 130.5 µΜ 13-SMG.
[0094] In some embodiments, a KO gene is expressed in a steviol glycoside-producing S.
cerevisiae strain that further overexpresses SrKAHel (SEQ ID NO:18, SEQ ID NO:68). In
some embodiments, expression of a KO gene of SEQ ID NO:55, SEQ ID NO:56, SEQ ID
NO:57, SEQ ID NO:58, SEQ ID NO:59, or SEQ ID NO:60, SEQ ID NO:65 in a steviol glycoside-
producing S. cerevisiae strain overexpressing SrKAHel results in higher expression of steviol
glycosides compared to a control steviol-glycoside producing strain or a steviol glycoside-
producing strain overexpressing SrKAHel (SEQ ID NO:18, SEQ ID NO:68). See Example 4.
[0095] In some embodiments, expression of a KO gene of SEQ ID NO:55, SEQ ID NO:56,
SEQ ID NO:57, or SEQ ID NO:60 in a steviol glycoside-producing S. cerevisiae strain
overexpressing SrKAHel (SEQ ID NO:18, SEQ ID NO:68) results in higher levels of
glycosylated ent-kaurenoic acid compared to a control S. cerevisiae strain. See Example 4.
[0096] In some embodiments, expression of a KO gene of SEQ ID NO:55, SEQ ID NO:56,
SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:60 in a steviol glycoside-producing S. cerevisiae
strain overexpressing SrKAHel (SEQ ID NO:18, SEQ ID NO;68) results in improved metabolic
conversion of a glycosylated ent-kaurenol intermediate compound relative to a control S.
cerevisiae strain or a steviol glycoside-producing S. cerevisiae strain overexpressing SrKAHel
(SEQ ID NO:18, SEQ ID NO:68). See Example 4.
[0097] In some embodiments, a KAH is a Prunus KAH, such as a Prunus avium, Prunus
mume, or Prunus persica KAH. In some embodiments, a KAH is a KAH of the CYP72A21 9 or
CYP71A219-like family. In some embodiments, the nucleotide sequence of a nucleic acid
encoding a KAH enzyme is set forth in SEQ ID NO:90 or SEQ ID NO:96. The nucleic acids of
SEQ ID NO:90 and SEQ ID NO:96 encode a KAH from Prunus avium with an amino acid
sequence set forth in SEQ ID NO:91 . In some embodiments, a KAH polypeptide is a
polypeptide with an amino acid sequence set forth in SEQ ID NO:92, SEQ ID NO:93, SEQ ID
NO:94, or SEQ ID NO:95. In some embodiments, a KAH polypeptide is a KAH polypeptide with
at least 50% sequence identity to an amino acid sequence set forth in SEQ ID NO:91, SEQ ID
NO:92, SEQ ID NO:93, SEQ ID NO:94, or SEQ ID NO:95. In some embodiments, expression
of a gene encoding a polypeptide having at least 50% sequence identity to an amino acid
sequence set forth in SEQ ID NO:91, SEQ ID NO:92, SEQ ID NO:93, SEQ ID NO:94, or SEQ
ID NO:95 in a recombinant host results in production of a steviol glycoside or steviol glycoside
precursor, such as 13-SMG and/or rubusoside. See Example 8.
[0098] In some embodiments, the nucleotide sequence of the nucleic acid encoding a CPR
enzyme is set forth in SEQ ID NO:23, SEQ ID NO:51, SEQ ID NO:61, SEQ ID NO:62, SEQ ID
NO:66, SEQ ID NO:67, or SEQ ID NO:97. In some aspects, the nucleic acid encoding the CPR
polypeptide has at least 75% identity to the nucleotide sequence set forth in SEQ ID NO:23,
SEQ ID NO:61, or SEQ ID NO:62, or at least 70% identity to the nucleotide sequence set forth
in SEQ ID NO:24, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:51, or SEQ ID NO:97. In some
embodiments, the amino acid sequence of the CPR enzyme is set forth in SEQ ID NO:22, SEQ
ID NO:28, SEQ ID NO:69, SEQ ID NO:73, SEQ ID NO:74, or SEQ ID NO:76, SEQ ID NO:87, or
SEQ ID NO:98. In some embodiments, a host cell comprises one or more copies of one or
more nucleic acids encoding a CPR enzyme.
[0099] In a non-limiting example, SrKAHel is activated by the S. cerevisiae CPR encoded
by gene NCP1 (YHR042W). Enhanced activation of the KAH encoded by SrKAHel is observed
when the Arabidopsis thaliana CPR encoded by the gene ATR2 (SEQ ID NO:51) or the S.
rebaudiana CPR encoded by the genes CPR7 (SEQ ID NO:23) or CPR8 (SEQ ID NO:24, SEQ
ID NO:28) are co-expressed in a recombinant cell. Amino acid sequences of the A. thaliana
polypeptides ATR1 and ATR2 are set forth in SEQ ID NO:25 and SEQ ID NO:26, respectively.
The S. rebaudiana polypeptides CPR7 and CPR8 are set forth in SEQ ID NO:27 and SEQ ID
NO:28, respectively.
[00100] In some embodiments, expression of CPR1 (SEQ ID NO:61, SEQ ID NO:76) or of
CPR7 in the steviol glycoside-producing S. cerevisiae strain co-expressing S. rebaudiana CPR8
(SEQ ID NO:24, SEQ ID NO:28) and A. thaliana ATR2 (SEQ ID NO:51) results in higher levels
of RebM compared to a control steviol glycoside-producing S. cerevisiae strain expressing S.
rebaudiana CPR8 (SEQ ID NO:24, SEQ ID NO:28) and A. thaliana ATR2 (SEQ ID N0:51). In
some embodiments, expression of the CPR set forth in SEQ ID NO:62 in a steviol glycoside-
producing S. cerevisiae strain overexpressing SrKAHel (SEQ ID NO: 18, SEQ ID NO:68) results
in higher levels of RebM compared to a steviol glycoside-producing S. cerevisiae strain that
does not express the nucleic acid set forth in SEQ ID NO:62 or overexpress SrKAHel. See
Example 5.
[00101] In some embodiments, co-expression of SrKOI (SEQ ID NO:59, SEQ ID NO:79) and
a CPR gene of SEQ ID NO:66 or SEQ ID NO:77 in a RebB-producing strain results in higher
production of 13-SMG and RebB than co-expression of a KO gene of SEQ ID NO:63 or SEQ ID
NO:64 and a CPR gene of SEQ ID NO:66 or SEQ ID NO:77. See Example 6.
[00102] In some embodiments, CPR1 (SEQ ID NO:61, SEQ ID NO:76) or CPR12 (SEQ ID
NO:97, SEQ ID NO:98) activates cytochrome c . In some embodiments, CPR1 (SEQ ID NO:61,
SEQ ID NO:76) or CPR12 (SEQ ID NO:97, SEQ ID NO:98) in the presence of SrKAHel (SEQ
ID NO:18, SEQ ID NO:68) activate cytochrome c . In some embodiments, CPR1 (SEQ ID
NO:61, SEQ ID NO:76) or CPR12 (SEQ ID NO:97, SEQ ID NO:98) regulate conversion of ent-
kaurenoic acid to steviol. In some embodiments, CPR1 (SEQ ID NO:61, SEQ ID NO:76) or
CPR12 (SEQ ID NO:97, SEQ ID NO:98) in combination with SrKAHel (SEQ ID NO: 18, SEQ ID
NO:68) convert ent-kaurenoic acid to steviol. In some embodiments, steviol production is
detected upon incubation of ent-kaurenoic acid with microsomal protein prepared from S.
cerevisiae strains expressing CPR1 (SEQ ID NO:61, SEQ ID NO:76) or CPR12 (SEQ ID NO:97,
SEQ ID NO:98) in combination with SrKAHel (SEQ ID NO:18, SEQ ID NO:68). In some
embodiments, expression of CPR1 (SEQ ID NO:61 , SEQ ID NO:76) or CPR12 (SEQ ID NO:97,
SEQ ID NO:98) in a recombinant host results in production of a steviol glycoside or steviol
glycoside precursor. See Example 9.
[00103] In some embodiments, a steviol glycoside-producing strain expresses a fusion
construct comprising a KO and the NADPH-dependent P450 oxidoreductase domain of
CYP102A1, referred to herein as "BMR." The codon-optimized nucleotide sequence encoding
the BMR polypeptide is set forth in SEQ ID NO:1 17; the BMR amino acid sequence is set forth
in SEQ ID NO: 1 18. In some embodiments, BMR is a mutant BMR, including, but not limited to a
BMR W 1046A mutant (SEQ ID NO:119, SEQ ID NO:120). The BMR mutant can be specific for
NADH. In some embodiments, the KO-BMR fusion construct comprises a linker (SEQ ID
NO:121, SEQ ID NO:122). In some embodiments, the KO of the fusion construct is SrKOI
(SEQ ID NO:59, SEQ ID NO:79) or the KO encoded by the nucleotide sequence set forth in
SEQ ID NO:65 (corresponding to the amino acid sequence set forth in SEQ ID N0.75). In some
embodiments, the KO of the fusion construct is a truncated KO. Exemplary KO-BMR fusion
constructs are set forth in SEQ ID NOs:99-1 12. See Example 10.
[00104] In some embodiments, expression of SrK01-BMR fusion constructs (SEQ ID
NOs:99-106) in a steviol glycoside-producing strain results in an increase in ent-kaurenoic acid,
13-SMG, and RebB levels, compared to expression of SrKOI (SEQ ID NO:59, SEQ ID NO:79)
in a steviol glycoside-producing strain. In some embodiments, expression of a fusion construct
(SEQ ID NO:107, SEQ ID NO:108) in a steviol glycoside-producing strain results in greater
conversion of ent-kaurene to ent-kaurenoic acid and greater conversion of ent-kaurenoic acid to
13-SMG, compared to expression of the KO encoded by the nucleotide sequence set forth in
SEQ ID NO:65 in a steviol glycoside-producing strain. In some embodiments, expression of a
fusion construct comprising the KO encoded by the nucleotide sequence set forth in SEQ ID
NO:65 and the W1046A mutant BMR (SEQ ID NO:109, SEQ ID NO:1 10) results in incrased ent-
kaurenoic acid levels. See Figure 16 (B and D) and Example 10.
[00105] In some embodiments, a steviol glycoside-producing strain comprises inheritance of
cortical ER protein 2 (ICE2; SEQ ID NO:1 13, SEQ ID NO:1 14). ICE2 is also referred to as
YIL090W. In some aspects, ICE2 is overexpressed. ICE2 can be expressed in a strain
comprising CPR1 (SEQ ID NO:61, SEQ ID NO:76) and/or CPR12 (SEQ ID NO:97, SEQ ID
NO:98). In some embodiments, a steviol glycoside-producing strain comprises two copies of
ICE2. In some embodiments, expression of ICE2 increases ent-kaurene metabolism (resulting
in decreased accumulation of ent-kaurene, ent-kaurenol, ent-kaurenal, and ent-kaurenol
glycosides), resulting in increased accumulation of steviol glycosides, compared to a control
strain. See Table 10 and Example 11.
[00106] In some embodiments, expression of the KO encoded by nucleotide sequence set
forth in SEQ ID NO:56 in a steviol glycoside-producing strain cultivated by fermentation results
in a lower accumulation of ent-kaurene compounds, compared to a control steviol glycoside-
producing strain. In some aspects, higher levels of ent-kaurenoic acid and steviol glycosides
result, as compared to a control strain. In some embodiments, expression of the KAH encoded
by nucleotide sequence set forth in SEQ ID NO:80, the KO encoded by nucleotide sequence set
forth in SEQ ID NO:56, and the KO encoded by nucleotide sequence set forth in SEQ ID NO:65
in a steviol glycoside-producing strain cultivated by fermentation results in decreased
accumulation of ent-kaurene, ent-kaurenol, ent-kaurenal, ent-kaurenol glycosides, ent-kaurenoic
acid, and ent-kaurenoic acid glycosides and increased production of steviol glycosides, as
compared to a control strain. In some embodiments, expression of CPR12 (SEQ ID NO:97,
SEQ ID NO:98), the KAH encoded by nucleotide sequence set forth in SEQ ID NO:80, and the
KO encoded by nucleotide sequence set forth in SEQ ID NO;56 cultivated by fermentation
results in decreased ent-kaurene, ent-kaurenol, ent-kaurenal, ent-kaurenol glycosides, ent-
kaurenoic acid, and ent-kaurenoic acid glycosides accumulation and higher levels of steviol
glycosides, as compared to a control strain. See Table 12 and Example 12.
Functional Homologs
[00107] Functional homologs of the polypeptides described above are also suitable for use in
producing steviol glycosides in a recombinant host. A functional homolog is a polypeptide that
has sequence similarity to a reference polypeptide, and that carries out one or more of the
biochemical or physiological function(s) of the reference polypeptide. A functional homolog and
the reference polypeptide can be a natural occurring polypeptide, and the sequence similarity
can be due to convergent or divergent evolutionary events. As such, functional homologs are
sometimes designated in the literature as homologs, or orthologs, or paralogs. Variants of a
naturally occurring functional homolog, such as polypeptides encoded by mutants of a wild type
coding sequence, can themselves be functional homologs. Functional homologs can also be
created via site-directed mutagenesis of the coding sequence for a polypeptide, or by combining
domains from the coding sequences for different naturally-occurring polypeptides ("domain
swapping"). Techniques for modifying genes encoding functional polypeptides described herein
are known and include, inter alia, directed evolution techniques, site-directed mutagenesis
techniques and random mutagenesis techniques, and can be useful to increase specific activity
of a polypeptide, alter substrate specificity, alter expression levels, alter subcellular location, or
modify polypeptide-polypeptide interactions in a desired manner. Such modified polypeptides
are considered functional homologs. The term "functional homolog" is sometimes applied to the
nucleic acid that encodes a functionally homologous polypeptide.
[00108] Functional homologs can be identified by analysis of nucleotide and polypeptide
sequence alignments. For example, performing a query on a database of nucleotide or
polypeptide sequences can identify homologs of steviol glycoside biosynthesis polypeptides.
Sequence analysis can involve BLAST, Reciprocal BLAST, or PSI-BLAST analysis of non-
redundant databases using a KO, KAH, or CPR amino acid sequence as the reference
sequence. Amino acid sequence is, in some instances, deduced from the nucleotide sequence.
Those polypeptides in the database that have greater than 40% sequence identity are
candidates for further evaluation for suitability as a steviol glycoside biosynthesis polypeptide.
Amino acid sequence similarity allows for conservative amino acid substitutions, such as
substitution of one hydrophobic residue for another or substitution of one polar residue for
another. If desired, manual inspection of such candidates can be carried out in order to narrow
the number of candidates to be further evaluated. Manual inspection can be performed by
selecting those candidates that appear to have domains present in steviol glycoside
biosynthesis polypeptides, e.g., conserved functional domains. In some embodiments, nucleic
acids and polypeptides are identified from transcriptome data based on expression levels rather
than by using BLAST analysis.
[00109] Conserved regions can be identified by locating a region within the primary amino
acid sequence of a steviol glycoside biosynthesis polypeptide that is a repeated sequence,
forms some secondary structure (e.g., helices and beta sheets), establishes positively or
negatively charged domains, or represents a protein motif or domain. See, e.g., the Pfam web
site describing consensus sequences for a variety of protein motifs and domains on the World
Wide Web at sanger.ac.uk/Software/Pfam/ and pfam.janelia.org/. The information included at
the Pfam database is described in Sonnhammer et al., Nucl. Acids Res., 26:320-322 (1998);
Sonnhammer et al., Proteins, 28:405-420 (1997); and Bateman et al., Nucl. Acids Res., 27:260-
262 (1999). Conserved regions also can be determined by aligning sequences of the same or
related polypeptides from closely related species. Closely related species preferably are from
the same family. In some embodiments, alignment of sequences from two different species is
adequate to identify such homologs.
[00110] Typically, polypeptides that exhibit at least about 40% amino acid sequence identity
are useful to identify conserved regions. Conserved regions of related polypeptides exhibit at
least 45% amino acid sequence identity (e.g., at least 50%, at least 60%, at least 70%, at least
80%, or at least 90% amino acid sequence identity). In some embodiments, a conserved region
exhibits at least 92%, 94%, 96%, 98%, or 99% amino acid sequence identity.
[00111] For example, polypeptides suitable for producing steviol in a recombinant host
include functional homologs of KO, KAH, and CPR.
[00112] Methods to modify the substrate specificity of, for example, KO, KAH, or CPR, are
known to those skilled in the art, and include without limitation site-directed/rational mutagenesis
approaches, random directed evolution approaches and combinations in which random
mutagenesis/saturation techniques are performed near the active site of the enzyme. For
example see Osmani et al., 2009, Phytochemistry 70: 325-347.
[00113] A candidate sequence typically has a length that is from 80% to 200% of the length
of the reference sequence, e.g., 82, 85, 87, 89, 90, 93, 95, 97, 99, 100, 105, 110, 115, 120, 130,
140, 150, 160, 170, 180, 190, or 200% of the length of the reference sequence. A functional
homolog polypeptide typically has a length that is from 95% to 105% of the length of the
reference sequence, e.g., 90, 93, 95, 97, 99, 100, 105, 110, 115, or 120% of the length of the
reference sequence, or any range between. A% identity for any candidate nucleic acid or
polypeptide relative to a reference nucleic acid or polypeptide can be determined as follows. A
reference sequence (e.g., a nucleic acid sequence or an amino acid sequence described
herein) is aligned to one or more candidate sequences using the computer program Clusta!W
{version 1.83, default parameters), which allows alignments of nucleic acid or polypeptide
sequences to be carried out across their entire length (global alignment). Chenna et a/., 2003,
Nucleic Acids Res. 31(13):3497-500.
[00114] CiustalW calculates the best match between a reference and one or more candidate
sequences, and aligns them so that identities, similarities and differences can be determined.
Gaps of one or more residues can be inserted into a reference sequence, a candidate
sequence, or both, to maximize sequence alignments. For fast pairwise alignment of nucleic
acid sequences, the following default parameters are used: word size: 2; window size: 4 ;
scoring method: % age; number of top diagonals: 4 ; and gap penalty: 5. For multiple alignment
of nucleic acid sequences, the following parameters are used: gap opening penalty: 10.0; gap
extension penalty: 5.0; and weight transitions: yes. For fast pairwise alignment of protein
sequences, the following parameters are used: word size: 1; window size: 5; scoring method :%
age; number of top diagonals: 5; gap penalty: 3 . For multiple alignment of protein sequences,
the following parameters are used: weight matrix: blosum; gap opening penalty: 10.0; gap
extension penalty: 0.05; hydrophilic gaps: on; hydrophilic residues: Gly, Pro, Ser, Asn, Asp, Gin,
Glu, Arg, and Lys; residue-specific gap penalties: on. The CiustalW output is a sequence
alignment that reflects the relationship between sequences. CiustalW can be run, for example,
at the Baylor College of Medicine Search Launcher site on the World Wide Web
(searchlauncher.bcm.tmc.edu/multi-align/multi-align.html) and at the European Bioinformatics
Institute site on the World Wide Web (ebi.ac.uk/clustalw).
[00115] To determine % identity of a candidate nucleic acid or amino acid sequence to a
reference sequence, the sequences are aligned using CiustalW, the number of identical
matches in the alignment is divided by the length of the reference sequence, and the result is
multiplied by 100. It is noted that the % identity value can be rounded to the nearest tenth. For
example, 78. 1 , 78. 12, 78. 13, and 78. 14 are rounded down to 78.1 , while 78.1 5, 78. 16 , 78. 17,
78. 18 , and 78. 19 are rounded up to 78.2.
[001 16] It will be appreciated that functional KO, KAH , or CPR proteins can include additional
amino acids that are not involved n the enzymatic activities carried out by the enzymes. n
some embodiments, KO, KAH, or CPR proteins are fusion proteins. The terms "chimera,"
"fusion polypeptide," "fusion protein," "fusion enzyme," "fusion construct," "chimeric protein,"
"chimeric polypeptide," "chimeric construct," and "chimeric enzyme" can be used
interchangeably herein to refer to proteins engineered through the joining of two or more genes
that code for different proteins. In some embodiments, a nucleic acid sequence encoding a KO,
KAH , or CPR polypeptide can include a tag sequence that encodes a "tag" designed to facilitate
subsequent manipulation (e.g. , to facilitate purification or detection), secretion, or localization of
the encoded polypeptide. Tag sequences can be inserted in the nucleic acid sequence
encoding the polypeptide such that the encoded tag is located at either the carboxyl or amino
terminus of the polypeptide. Non-limiting examples of encoded tags include green fluorescent
protein (GFP), human influenza hemagglutinin (HA), glutathione S transferase (GST),
polyhistidine-tag (HIS tag), and Flag ™ tag (Kodak, New Haven, CT). Other examples of tags
include a chloroplast transit peptide, a mitochondrial transit peptide, an amyloplast peptide,
signal peptide, or a secretion tag.
[001 7] In some embodiments, a fusion protein is a protein altered by domain swapping. A s
used herein, the term "domain swapping" is used to describe the process of replacing a domain
of a first protein with a domain of a second protein. In some embodiments, the domain of the
first protein and the domain of the second protein are functionally identical or functionally
similar. In some embodiments, the structure and/or sequence of the domain of the second
protein differs from the structure and/or sequence of the domain of the first protein. In some
embodiments, a KO polypeptide is altered by domain swapping. See Example 10.
Steviol and Steviol Glycoside Biosynthesis Nucleic Acids
[001 18] A recombinant gene encoding a polypeptide described herein comprises the coding
sequence for that polypeptide, operably linked in sense orientation to one or more regulatory
regions suitable for expressing the polypeptide. Because many microorganisms are capable of
expressing multiple gene products from a polycistronic mRNA, multiple polypeptides can be
expressed under the control of a single regulatory region for those microorganisms, if desired.
A coding sequence and a regulatory region are considered to be operably linked when the
regulatory region and coding sequence are positioned so that the regulatory region is effective
for regulating transcription or translation of the sequence. Typically, the translation initiation site
of the translational reading frame of the coding sequence is positioned between one and about
fifty nucleotides downstream of the regulatory region for a monocistronic gene.
[00119] In many cases, the coding sequence for a polypeptide described herein is identified
in a species other than the recombinant host, i.e., is a heterologous nucleic acid. Thus, if the
recombinant host is a microorganism, the coding sequence can be from other prokaryotic or
eukaryotic microorganisms, from plants or from animals. In some case, however, the coding
sequence is a sequence that is native to the host and is being reintroduced into that organism.
A native sequence can often be distinguished from the naturally occurring sequence by the
presence of non-natural sequences linked to the exogenous nucleic acid, e.g., non-native
regulatory sequences flanking a native sequence in a recombinant nucleic acid construct. In
addition, stably transformed exogenous nucleic acids typically are integrated at positions other
than the position where the native sequence is found. "Regulatory region" refers to a nucleic
acid having nucleotide sequences that influence transcription or translation initiation and rate,
and stability and/or mobility of a transcription or translation product. Regulatory regions include,
without limitation, promoter sequences, enhancer sequences, response elements, protein
recognition sites, inducible elements, protein binding sequences, 5 ' and 3 ' untrans regions
(UTRs), transcriptional start sites, termination sequences, polyadenylation sequences, introns,
and combinations thereof. A regulatory region typically comprises at least a core (basal)
promoter. A regulatory region also may include at least one control element, such as an
enhancer sequence, an upstream element or an upstream activation region (UAR). A
regulatory region is operably linked to a coding sequence by positioning the regulatory region
and the coding sequence so that the regulatory region is effective for regulating transcription or
translation of the sequence. For example, to operably link a coding sequence and a promoter
sequence, the translation initiation site of the translational reading frame of the coding sequence
is typically positioned between one and about fifty nucleotides downstream of the promoter. A
regulatory region can, however, be positioned as much as about 5,000 nucleotides upstream of
the translation initiation site, or about 2,000 nucleotides upstream of the transcription start site.
[00120] The choice of regulatory regions to be included depends upon several factors,
including, but not limited to, efficiency, selectability, inducibility, desired expression level, and
preferential expression during certain culture stages. It is a routine matter for one of skill in the
art to modulate the expression of a coding sequence by appropriately selecting and positioning
regulatory regions relative to the coding sequence. It will be understood that more than one
regulatory region may be present, e.g., introns, enhancers, upstream activation regions,
transcription terminators, and inducible elements.
[00121] One or more genes can be combined in a recombinant nucleic acid construct in
"modules" useful for a discrete aspect of steviol and/or steviol glycoside production. Combining
a plurality of genes in a module, particularly a polycistronic module, facilitates the use of the
module in a variety of species. For example, a steviol biosynthesis gene cluster, or a UGT gene
cluster, can be combined in a polycistronic module such that, after insertion of a suitable
regulatory region, the module can be introduced into a wide variety of species. As another
example, a UGT gene cluster can be combined such that each UGT coding sequence is
operably linked to a separate regulatory region, to form a UGT module. Such a module can be
used in those species for which monocistronic expression is necessary or desirable. In addition
to genes useful for steviol or steviol glycoside production, a recombinant construct typically also
contains an origin of replication, and one or more selectable markers for maintenance of the
construct in appropriate species.
[00122] It will be appreciated that because of the degeneracy of the genetic code, a number
of nucleic acids can encode a particular polypeptide; i.e., for many amino acids, there is more
than one nucleotide triplet that serves as the codon for the amino add. Thus, codons in the
coding sequence for a given polypeptide can be modified such that optimal expression in a
particular host is obtained, using appropriate codon bias tables for that host (e.g.,
microorganism). As iso nucleic acids, these modified sequences can exist as purified
molecules and can be incorporated into a vector or a virus for use in constructing modules for
recombinant nucleic acid constructs.
[0003] In some cases, it is desirable to inhibit one or more functions of an endogenous
polypeptide in order to divert metabolic intermediates towards steviol or steviol glycoside
biosynthesis. For example, it may be desirable to downregulate synthesis of sterols in a yeast
strain in order to further increase steviol or steviol glycoside production, e.g., by downregulating
squalene epoxidase. As another example, it may be desirable to inhibit degradative functions of
certain endogenous gene products, e.g., glycohydrolases that remove glucose moieties from
secondary metabolites or phosphatases as discussed herein. In such cases, a nucleic acid that
overexpresses the polypeptide or gene product may be included in a recombinant construct that
is transformed into the strain. Alternatively, mutagenesis can be used to generate mutants in
genes for which it is desired to increase or enhance function.
Host Microorganisms
[00123] Recombinant hosts can be used to express polypeptides for the producing steviol
glycosides, including mammalian, insect, plant, and algal cells. A number of prokaryotes and
eukaryotes are also suitable for use in constructing the recombinant microorganisms described
herein, e.g., gram-negative bacteria, yeast, and fungi. A species and strain selected for use as
a steviol glycoside production strain is first analyzed to determine which production genes are
endogenous to the strain and which genes are not present. Genes for which an endogenous
counterpart is not present in the strain are advantageously assembled in one or more
recombinant constructs, which are then transformed into the strain in order to supply the
missing function(s).
[00124] Typically, the recombinant microorganism is grown in a fermenter at a defined
temperature(s) for a desired period of time. The constructed and genetically engineered
microorganisms provided by the invention can be cultivated using conventional fermentation
processes, including, inter alia, chemostat, batch, fed-batch cultivations, semi-continuous
fermentations such as draw and fill, continuous perfusion fermentation, and continuous
perfusion cell culture. Depending on the particular microorganism used in the method, other
recombinant genes such as isopentenyl biosynthesis genes and terpene synthase and cyclase
genes may also be present and expressed. Levels of substrates and intermediates, e.g.,
isopentenyl diphosphate, dimethylailyl diphosphate, GGPP, ent-kaurene and ent-kaurenoic acid,
can be determined by extracting samples from culture media for analysis according to published
methods.
[00125] Carbon sources of use in the instant method include any molecule that can be
metabolized by the recombinant host cell to facilitate growth and/or production of the steviol
glycosides. Examples of suitable carbon sources include, but are not limited to, sucrose (e.g.,
as found in molasses), fructose, xylose, ethanol, glycerol, glucose, cellulose, starch, cellobiose
or other glucose-comprising polymer. In embodiments employing yeast as a host, for example,
carbons sources such as sucrose, fructose, xylose, ethanol, glycerol, and glucose are suitable.
The carbon source can be provided to the host organism throughout the cultivation period or
alternatively, the organism can be grown for a period of time in the presence of another energy
source, e.g., protein, and then provided with a source of carbon only during the fed-batch
phase.
[00126] After the recombinant microorganism has been grown in culture for the desired
period of time, steviol and/or one or more steviol glycosides can then be recovered from the
culture using various techniques known in the art. In some embodiments, a permeabilizing
agent can be added to aid the feedstock entering into the host and product getting out. For
example, a crude iysate of the cultured microorganism can be centrifuged to obtain a
supernatant. The resulting supernatant can then be applied to a chromatography column, e.g.,
a C-18 column, and washed with water to remove hydrophilic compounds, followed by elution of
the compound(s) of interest with a solvent such as methanol. The compound(s) can then be
further purified by preparative HPLC. See also, WO 2009/140394.
[00127] It will be appreciated that the various genes and modules discussed herein can be
present in two or more recombinant hosts rather than a single host. When a plurality of
recombinant hosts is used, they can be grown in a mixed culture to accumulate steviol and/or
steviol glycosides.
[00128] Alternatively, the two or more hosts each can be grown in a separate culture medium
and the product of the first culture medium, e.g., steviol, can be introduced into second culture
medium to be converted into a subsequent intermediate, or into an end product such as, for
example, RebA. The product produced by the second, or final host is then recovered. It will
also be appreciated that in some embodiments, a recombinant host is grown using nutrient
sources other than a culture medium and utilizing a system other than a fermenter.
[00129] Exemplary prokaryotic and eukaryotic species are described in more detail below.
However, it will be appreciated that other species can be suitable. For example, suitable species
can be in a genus such as Agaricus, Aspergillus, Bacillus, Candida, Corynebacteriurn,
Eremothecium, Escherichia, Fusarium/Cibberella, Kluyveromyces, Laetiporus, Lentinus,
Phaffia, Phanerochaete, Pichia, Physcomitrella, Rhodoturu!a, Saccharomyces,
Schizosaccharomyces, Sphaceloma, Xanthophyllomyces or Yarrowia. Exemplary species from
such genera include Lentinus tigrinus, Laetiporus sulphureus, Phanerochaete chrysosporium,
Pichia pastoris, Cyberlindnera jadinii, Physcomitrella patens, Rhodoturula glutinis, Rhodoturula
mucilaginosa, Phaffia rhodozyma, Xanthophyllomyces dendrorhous, Fusarium
fujikuroi/Gibberella fujikuroi, Candida utilis, Candida glabrata, Candida albicans, and Yarrowia
lipolytica.
[00130] In some embodiments, a microorganism can be a prokaryote such as Escherichia
bacteria cells, for example, Escherichia coli cells; Lactobacillus bacteria cells; Lactococcus
bacteria cells; Cornebacterium bacteria cells; Acetobacter bacteria cells; Acinetobacter bacteria
cells; or Pseudomonas bacterial cells.
[00131] n some embodiments, a microorganism can be an Ascomycete such as Gibberella
fujikuroi, Kluyveromyces lactis, Schizosaccharomyces pombe, Aspergillus niger, Yarrowia
lipolytica, Ashbya gossypii, or S. cerevisiae.
[00132] in some embodiments, a microorganism can be an algal cell such as Blakeslea
trispora, Dunaliella salina, Haematococcus pluvialis, Chlorella sp., Undaria pinnatifida,
Sargassum, Laminaria japonica, Scenedesmus almeriensis species.
[00133] In some embodiments, a microorganism can be a cyanobacterial cell such as
Blakeslea trispora, Dunaliella salina, Haematococcus pluvialis, Chlorella sp., Undaria
pinnatifida, Sargassum, Laminaria japonica, Scenedesmus almeriensis.
Saccharomyces spp.
[00134] Saccharomyces is a widely used chassis organism in synthetic biology, and can be
used as the recombinant microorganism platform. For example, there are libraries of mutants,
plasmids, detailed computer models of metabolism and other information available for S.
cerevisiae, allowing for rational design of various modules to enhance product yield. Methods
are known for making recombinant microorganisms.
Aspergillus spp.
[001 35] Aspergillus species such as A. oryzae, A. niger and A. sojae are widely used
microorganisms in food production and can also be used as the recombinant microorganism
platform. Nucleotide sequences are available for genomes of A. nidulans, A. fumigatus, A.
oryzae, A. clavatus, A. flavus, A. niger, and A. terreus, allowing rational design and modification
of endogenous pathways to enhance flux and increase product yield. Metabolic models have
been developed for Aspergillus, as well as transcriptomtc studies and proteomics studies. A.
niger is cultured for the industrial production of a number of food ingredients such as citric acid
and gluconic acid, and thus species such as A. niger are generally suitable for producing steviol
glycosides.
∞
[00136] E. coli, another widely used platform organism in synthetic biology, can also be used
as the recombinant microorganism platform. Similar to Saccharomyces, there are libraries of
mutants, plasmids, detailed computer models of metabolism and other information available for
E. coli, allowing for rational design of various modules to enhance product yield. Methods
similar to those described above for Saccharomyces can be used to make recombinant E. coli
microorganisms.
Agaricus. Gibberella, and Phanerochaete SOD.
[00137] Agaricus, Gibberella, and Phanerochaete spp. can be useful because they are
known to produce large amounts of isoprenoids in culture. Thus, the terpene precursors for
producing large amounts of steviol glycosides are already produced by endogenous genes.
Thus, modules comprising recombinant genes for steviol glycoside biosynthesis polypeptides
can be introduced into species from such genera without the necessity of introducing
mevalonate or MEP pathway genes.
Arxuia adeninivorans (Blastobotrys adeninivorans)
[00138] Arxuia adeninivorans is dimorphic yeast (it grows as budding yeast like the baker's
yeast up to a temperature of 42°C, above this threshold it grows in a filamentous form) with
unusual biochemical characteristics. It can grow on a wide range of substrates and can
assimilate nitrate. It has successfully been applied to the generation of strains that can produce
natural plastics or the development of a biosensor for estrogens in environmental samples.
Yarrowia lipolytica
[00139] Yarrowia lipolytica is dimorphic yeast (see Arxuia adeninivorans) and belongs to the
family Hemiascomycetes. The entire genome of Yarrowia lipolytica is known. Yarrowia species
is aerobic and considered to be non-pathogenic. Yarrowia is efficient in using hydrophobic
substrates (e.g. aikanes, fatty acids, oils) and can grow on sugars. It has a high potential for
industrial applications and is an oleaginous microorgamism. Yarrowia lipolyptica can
accumulate lipid content to approximately 40% of its dry cell weight and is a model organism for
lipid accumulation and remobilization. See e.g., Nicaud, 2012, Yeast 29(1 0):409-1 8; Beopoulos
et a!., 2009, Biochimie 91(6):692-6; Bankar et a/., 2009, Appl Microbiol Biotechnol. 84(5):847-
65.
Rhodotorula so.
[00140] Rhodotorula is unicellular, pigmented yeast. The oleaginous red yeast, Rhodotorula
glutinis, has been shown to produce lipids and carotenoids from crude glycerol (Saenge et al.,
201 1 , Process Biochemistry 46(1 ):21 0-8). Rhodotorula toruloides strains have been shown to
be an efficient fed-batch fermentation system for improved biomass and lipid productivity (Li et
al., 2007, Enzyme and Microbial Technology 41:31 2-7).
Rhodosporidium toruioides
[00141] Rhodosporidium toruioides is oleaginous yeast and useful for engineering iipid-
production pathways (See e.g. Zhu et al., 2013, Nature Commun. 3:1 112; Ageitos et al., 201 1,
Applied Microbiology and Biotechnology 90(4): 12 19-27).
Candida boidinii
[00142] Candida boidinii is methylotrophic yeast (it can grow on methanol). Like other
methylotrophic species such as Hansenula polymorpha and Pichia pastoris, it provides an
excellent platform for producing heterologous proteins. Yields in a multigram range of a
secreted foreign protein have been reported. A computational method, IPRO, recently predicted
mutations that experimentally switched the cofactor specificity of Candida boidinii xylose
reductase from NADPH to NADH. See, e.g., Mattanovich et al., 2012, Methods Mol Biol.
824:329-58; Khoury et al., 2009, Protein Sci. 18(1 0):21 25-38.
Hansenula polymorpha (Pichia anousta)
[00143] Hansenula polymorpha is methylotrophic yeast (see Candida boidinii). It can
furthermore grow on a wide range of other substrates; it is thermo-tolerant and can assimilate
nitrate (see also Kluyveromyces lactis). It has been applied to producing hepatitis B vaccines,
insulin and interferon alpha-2a for the treatment of hepatitis C, furthermore to a range of
technical enzymes. See, e.g., Xu et al., 2014, Virol Sin. 29(6):403-9.
Kluyveromyces lactis
[00144] Kluyveromyces lactis is yeast regularly applied to the production of kefir. It can grow
on several sugars, most importantly on lactose which is present in milk and whey. It has
successfully been applied among others for producing chymosin (an enzyme that is usually
present in the stomach of calves) for producing cheese. Production takes place in fermenters on
a 40,000 L scale. See, e.g., van Ooyen e al., 2006, FEMS Yeast Res. 6(3):381-92.
Pichia pastoris
[00145] Pichia pastoris is methylotrophic yeast (see Candida boidinii and Hansenula
polymorpha). It provides an efficient platform for producing foreign proteins. Platform elements
are available as a kit and it is worldwide used in academia for producing proteins. Strains have
been engineered that can produce complex human N-glycan (yeast glycans are similar but not
identical to those found in humans). See, e.g., Piirainen et al., 2014, N Biotechnol. 31(6):532-7.
Physcomitrella spp.
[00146] Physcomitrella mosses, when grown in suspension culture, have characteristics
similar to yeast or other fungal cultures. This genera can be used for producing plant secondary
metabolites, which can be difficult to produce in other types of cells.
Steviol Glycoside Compositions
[00147] Steviol glycosides do not necessarily have equivalent performance in different food
systems. It is therefore desirable to have the ability to direct the synthesis to steviol glycoside
compositions of choice. Recombinant hosts described herein can produce compositions that
are selectively enriched for specific steviol glycosides (e.g., RebD or Reb ) and have a
consistent taste profile. As used herein, the term "enriched" is used to describe a steviol
glycoside composition with an increased proportion of a particular steviol glycoside, compared
to a steviol glycoside composition (extract) from a stevia plant. Thus, the recombinant hosts
described herein can facilitate the production of compositions that are tailored to meet the
sweetening profile desired for a given food product and that have a proportion of each steviol
glycoside that is consistent from batch to batch. In some embodiments, hosts described herein
do not produce or produce a reduced amount of undesired plant by-products found in Stevia
extracts. Thus, steviol glycoside compositions produced by the recombinant hosts described
herein are distinguishable from compositions derived from Stevia plants.
[00148] The amount of an individual steviol glycoside (e.g., RebA, RebB, RebD, or RebM)
accumulated can be from about 1 to about 7,000 mg/L, e.g., about 1 to about 10 mg/L, about 3
to about 10 mg/L, about 5 to about 20 mg/L, about 10 to about 50 mg/L, about 1 to about 100
mg/L, about 25 to about 500 mg/L, about 100 to about 1,500 mg/L, or about 200 to about 1,000
mg/L, at least about 1,000 mg/L, at least about 1,200 mg/L, at least about at least 1,400 mg/L,
at least about 1,600 mg/L, at least about 1,800 mg/L, at least about 2,800 mg/L, or at least
about 7,000 mg/L. In some aspects, the amount of an individual steviol glycoside can exceed
7,000 mg/L. The amount of a combination of steviol glycosides (e.g., RebA, RebB, RebD, or
RebM) accumulated can be from about 1 mg/L to about 7,000 mg/L, e.g., about 200 to about
1,500, at least about 2,000 mg/L, at least about 3,000 mg/L, at least about 4,000 mg/L, at least
about 5,000 mg/L, at least about 6,000 mg/L, or at least about 7,000 mg/L. In some aspects,
the amount of a combination of steviol glycosides can exceed 7,000 mg/L. In general, longer
culture times will lead to greater amounts of product. Thus, the recombinant microorganism can
be cultured for from 1 day to 7 days, from 1 day to 5 days, from 3 days to 5 days, about 3 days,
about 4 days, or about 5 days.
[00149] It will be appreciated that the various genes and modules discussed herein can be
present in two or more recombinant microorganisms rather than a single microorganism. When
a plurality of recombinant microorganisms is used, they can be grown in a mixed culture to
produce steviol and/or steviol glycosides. For example, a first microorganism can comprise one
or more biosynthesis genes for producing a steviol glycoside precursor, while a second
microorganism comprises steviol glycoside biosynthesis genes. The product produced by the
second, or final microorganism is then recovered. It will also be appreciated that in some
embodiments, a recombinant microorganism is grown using nutrient sources other than a
culture medium and utilizing a system other than a fermenter.
[00150] Alternatively, the two or more microorganisms each can be grown in a separate
culture medium and the product of the first culture medium, e.g., steviol, can be introduced into
second culture medium to be converted into a subsequent intermediate, or into an end product
such as RebA. The product produced by the second, or final microorganism is then recovered.
It will also be appreciated that in some embodiments, a recombinant microorganism is grown
using nutrient sources other than a culture medium and utilizing a system other than a
fermenter.
[00151] Steviol glycosides and compositions obtained by the methods disclosed herein can
be used to make food products, dietary supplements and sweetener compositions. See, e.g.,
WO 201 1/153378, WO 2013/022989, WO 2014/122227, and WO 2014/122328.
[00152] For example, substantially pure steviol or steviol glycoside such as Reb or RebD
can be included in food products such as ice cream, carbonated beverages, fruit juices, yogurts,
baked goods, chewing gums, hard and soft candies, and sauces. Substantially pure steviol or
steviol glycoside can also be included in non-food products such as pharmaceutical products,
medicinal products, dietary supplements and nutritional supplements. Substantially pure steviol
or steviol glycosides may also be included in animal feed products for both the agriculture
industry and the companion animal industry. Alternatively, a mixture of steviol and/or steviol
glycosides can be made by culturing recombinant microorganisms separately, each producing a
specific steviol or steviol glycoside, recovering the steviol or steviol glycoside in substantially
pure form from each microorganism and then combining the compounds to obtain a mixture
comprising each compound in the desired proportion. The recombinant microorganisms
described herein permit more precise and consistent mixtures to be obtained compared to
current Stevia products.
[00153] In another alternative, a substantially pure steviol or steviol glycoside can be
incorporated into a food product along with other sweeteners, e.g. saccharin, dextrose, sucrose,
fructose, erythritol, aspartame, sucralose, monatin, or acesulfame potassium. The weight ratio
of steviol or steviol glycoside relative to other sweeteners can be varied as desired to achieve a
satisfactory taste in the final food product. See, e.g., U.S. 2007/0128311. In some
embodiments, the steviol or steviol glycoside may be provided with a flavor (e.g., citrus) as a
flavor modulator.
[00154] Compositions produced by a recombinant microorganism described herein can be
incorporated into food products. For example, a steviol glycoside composition produced by a
recombinant microorganism can be incorporated into a food product in an amount ranging from
about 20 g steviol glycoside/kg food product to about 1800 mg steviol glycoside/kg food
product on a dry weight basis, depending on the type of steviol glycoside and food product. For
example, a steviol glycoside composition produced by a recombinant microorganism can be
incorporated into a dessert, cold confectionary (e.g., ice cream), dairy product (e.g., yogurt), or
beverage (e.g., a carbonated beverage) such that the food product has a maximum of 500 mg
steviol glycoside/kg food on a dry weight basis. A steviol glycoside composition produced by a
recombinant microorganism can be incorporated into a baked good (e.g., a biscuit) such that the
food product has a maximum of 300 mg steviol glycoside/kg food on a dry weight basis. A
steviol glycoside composition produced by a recombinant microorganism can be incorporated
into a sauce (e.g., chocolate syrup) or vegetable product (e.g., pickles) such that the food
product has a maximum of 1000 mg steviol glycoside/kg food on a dry weight basis. A steviol
glycoside composition produced by a recombinant microorganism can be incorporated into a
bread such that the food product has a maximum of 160 mg steviol glycoside/kg food on a dry
weight basis. A steviol glycoside composition produced by a recombinant microorganism, plant,
or plant cell can be incorporated into a hard or soft candy such that the food product has a
maximum of 1600 mg steviol glycoside/kg food on a dry weight basis. A steviol glycoside
composition produced by a recombinant microorganism, plant, or plant cell can be incorporated
into a processed fruit product (e.g., fruit juices, fruit filling, jams, and jellies) such that the food
product has a maximum of 1000 mg steviol glycoside/kg food on a dry weight basis. In some
embodiments, a steviol glycoside composition produced herein is a component of a
pharmaceutical composition. See, e.g., Steviol Glycosides Chemical and Technical
Assessment 69th JECFA, 2007, prepared by Harriet Wailin, Food Agric. Org.; EFSA Panel on
Food Additives and Nutrient Sources added to Food (ANS), "Scientific Opinion on the safety of
steviol glycosides for the proposed uses as a food additive," 2010, EFSA Journal 8(4): 1537;
U.S. Food and Drug Administration GRAS Notice 323; U.S Food and Drug Administration
GRAS Notice Notice 329; WO 201 1/037959; WO 2010/146463; WO 201 1/046423; and W O
2011/056834.
[001 55] For example, such a steviol glycoside composition can have from 90-99 weight %
RebA and an undetectable amount of stevia plant-derived contaminants, and be incorporated
into a food product at from 25-1600 mg/kg, e.g., 100-500 mg/kg, 25-100 mg/kg, 250-1000
mg/kg, 50-500 mg/kg or 500-1 000 mg/kg on a dry weight basis.
[00156] Such a steviol glycoside composition can be a RebB-enriched composition having
greater than 3 weight % RebB and be incorporated into the food product such that the amount
of RebB in the product is from 25-1600 mg/kg, e.g., 100-500 mg/kg, 25-100 mg/kg, 250-1000
mg/kg, 50-500 mg/kg or 500-1 000 mg/kg on a dry weight basis. Typically, the RebB-enriched
composition has an undetectable amount of stevia plant-derived contaminants.
[001 57] Such a steviol glycoside composition can be a RebD-enriched composition having
greater than 3 weight % RebD and be incorporated into the food product such that the amount
of RebD in the product is from 25-1600 mg/kg, e.g., 100-500 mg/kg, 25-100 mg/kg, 250-1000
mg/kg, 50-500 mg/kg or 500-1000 mg/kg on a dry weight basis. Typically, the RebD-enriched
composition has an undetectable amount of stevia plant-derived contaminants.
[00158] Such a steviol glycoside composition can be a RebE-enriched composition having
greater than 3 weight % RebE and be incorporated into the food product such that the amount
of RebE in the product is from 25-1600 mg/kg, e.g., 100-500 mg/kg, 25-100 mg/kg, 250-1000
mg/kg, 50-500 mg/kg or 500-1000 mg/kg on a dry weight basis. Typically, the RebE-enriched
composition has an undetectable amount of stevia plant-derived contaminants.
[00159] Such a steviol glycoside composition can be a RebM-enriched composition having
greater than 3 weight % RebM and be incorporated into the food product such that the amount
of RebM in the product is from 25-1600 mg/kg, e.g., 100-500 mg/kg, 25-100 mg/kg, 250-1000
mg/kg, 50-500 mg/kg or 500-1000 mg/kg on a dry weight basis. Typically, the RebM-enriched
composition has an undetectable amount of stevia plant-derived contaminants.
[00160] In some embodiments, a substantially pure steviol or steviol glycoside is
incorporated into a tabletop sweetener or "cup-for-cup" product. Such products typically are
diluted to the appropriate sweetness level with one or more bulking agents, e.g., maltodextrins,
known to those skilled in the art. Steviol glycoside compositions enriched for RebA, RebB,
RebD, RebE, or RebM, can be package in a sachet, for example, at from 10,000 to 30,000 mg
steviol glycoside/kg product on a dry weight basis, for tabletop use. In some embodiments, a
stevio! glycoside produced in vitro, in vivo, or by whole cell byconversion
[00161] The invention will be further described in the following examples, which do not limit
the scope of the invention described in the claims.
EXAMPLES
[00162] The Examples that follow are illustrative of specific embodiments of the invention,
and various uses thereof. They are set forth for explanatory purposes only, and are not to be
taken as limiting the invention.
Example 1. LC-MS Analytical Procedures
[00163] Three LC-MS procedures were used herein. In the first method used for Examples
2-6, LC-MS analyses were performed using an Ultimate 3000 UPLC system (Dionex) fitted with
a Waters Acquity UPLC ®BEH shield RP18 column (2.1 x 50 mm, 1.7 µm particles, 130 A pore
size) connected to a TSQ Quantum Access (ThermoFisher Scientific) triple quadropole mass
spectrometer with a heated electrospray ion (HESI) source. Elution was carried out using a
mobile phase of eluent B (MeCN with 0.1% formic acid) and eluent A (water with 0.1% formic
acid) by increasing the gradient from 25% to 47% B from min 0.0 to 4.0, increasing 47% to
100% B from min 4.0 to 5.0, and holding 100% B from min 5.0 to 6.5. The flow rate was 0.4
mL/min and the column temperature 35°C. Steviol glycosides were detected using SIM (Single
Ion Monitoring) with the following m/z-traces.
Table 1A: LC-MS analytical information for Steviol Glycosides.
[001 64] in the second method used for Examples 7, 8 , and 10, LC-MS analyses were
performed on Waters ACQUITY UPLC (Waters Corporation, Milford, MA) with coupled to a
Waters ACQUITY ESI (electrospray ionization)-TQD triple quadropole mass spectrometer.
Compound separation was achieved on Waters ACQUITY UPLC® BEH C18 column (2.1 x 50
mm, 1.7 pm particles, 130 A pore size) equipped with ACQUITY UPLC BEH C18 VanGuard
pre-column (130 A, 1.7 pm, 2.1 mm X 5 mm) by using a gradient of the two mobile phases: A
(Water with 0.1% formic acid) and B (Acetonitrile with 0.1% formic acid)increasing B from 20%
to 50% between 0.3 to 2.0 min up to 100% at 2.01 min, holding to 100% for 0.6 min, and re-
equilibrating for 0.6 min. The flow rate was 0.6 m L/ min, and the column temperature was 55°C.
The MS acquisition was in negative ion-mode using SIM mode (Single Ion Monitoring). Stevioi
glycoside quantification was done by comparison with authentic standards.
Table 1B: MS analytical information for Steviol Glycosides.
[00165] in the third method used for Example 9, LC-MS analyses were performed on
Waters ACQUITY UPLC (Waters Corporation, Milford, MA) using a Waters Acquity UPLC®
BEH C18 column (2.1 x 50 mm, 1.7 pm particles, 130 A) coupled to a Waters single quadropole
mass spectrometer (SQD), equipped with an ESI and operated in negative mode. Compound
separation was achieved by a gradient of the two mobile phases: A (water with 0.1% formic
acid) and B (acetonitrile with 0.1% formic acid) by increasing from 60% to 100% B between 0.3
to 2.5 min, holding 100% B for 0.1 min, and re-equilibrating for 0.2 min. The flow rate was 0.6
m L/ min, and the column temperature was set at 55°C. Steviol or ent-kaurenoic acid was
monitored using SIM (Single Ion Monitoring) and quantified by comparing with authentic
standards.
Table 1C: MS analytical information for steviol and ent-kaurenoic acid.
Example 2. Construction of Steviol Glycoside-Producing and RebB-Producing Yeast
Strains
[00166] Steviol glycoside-producing S. cerevisiae strains were constructed as described in
WO 201 1/153378, WO 2013/022989, WO 2014/122227, and WO 2014/122328. For example, a
yeast strain comprising a recombinant gene encoding a Synechococcus sp. GGPPS (SEQ ID
NO:49) polypeptide, a recombinant gene encoding a truncated Zea mays CDPS (SEQ ID
NO:37) polypeptide, a recombinant gene encoding an A. thaliana KS (SEQ ID NO:6)
polypeptide, a recombinant gene encoding an S. rebaudiana KO (SEQ ID NO:59, SEQ ID
NO:79) polypeptide, a recombinant gene encoding an A. thaliana ATR2 (SEQ ID NO:51, SEQ
ID NO:87) polypeptide, a recombinant gene encoding an O. sativa EUGT1 1 (SEQ ID NO:86)
polypeptide, a recombinant gene encoding an SrKAHel (SEQ ID NO:18, SEQ ID NO:68)
polypeptide, a recombinant gene encoding an S. rebaudiana CPR8 (SEQ ID NO:24, SEQ ID
NO:28) polypeptide, a recombinant gene encoding an S. rebaudiana UGT85C2 (SEQ ID NO:30)
polypeptide, a recombinant gene encoding an S. rebaudiana UGT74G1 (SEQ ID NO:29)
polypeptide, a recombinant gene encoding an S, rebaudiana UGT76G1 (SEQ ID NO:2)
polypeptide, and a recombinant gene encoding an S. rebaudiana UGT91D2 variant,
UGT91D2e-b (SEQ ID NO:88), polypeptide accumulated steviol glycosides.
[00167] The UGT91D2e-b variant of UGT91D2 (SEQ ID NO:5 from PCT/US201 2/050021)
includes a substitution of a methionine for leucine at position 2 11 and a substitution of an
alanine for valine at position 286. Additional variants can include variants (except T144S,
M152L, L213F, S364P, and G384C variants) described in Table 14 and Example 11 of the
PCT/US201 2/050021 . GeneArt codon-optimized sequence encoding a S. rebaudiana
UGT91D2e-b with the amino acid modifications L21 1M and V286A (SEQ ID NO:88 for amino
acid sequence; codon optimized nucleotide sequence is set forth in SEQ ID NO:89) and
expressed from the native yeast TDH3 promoter and foiiowed by the native yeast CYC1
terminator.
[00168] Cells were grown in Synthetic Complete (SC) medium at 30°C for 5 days with
shaking (400 rpm for deep wells and 200 rpm for 15 ml_ Falcon growth tubes) prior to harvest.
Culture samples (without cell removal) were heated in the presence of DMSO for detection of
total glycoside levels with LC-MS. The strain accumulated total amounts of RebD of over 2500
mg/L, total amounts of RebM of over 2500 mg/L, and total amounts of RebA of over 700 mg/L.
See WO 2014/122227.
[00169] A separate S. cerevisiae strain was constructed to accumulate RebB. This strain
comprised a recombinant gene encoding a Synechococcus sp. GGPPS (SEQ ID NO:49)
polypeptide, a recombinant gene encoding a truncated Z. mays CDPS (SEQ ID NO:37)
polypeptide, a recombinant gene encoding an A. thaliana KS (SEQ ID NO:6) polypeptide, a
recombinant gene encoding an S. rebaudiana KO (SEQ ID NO:59, SEQ D NO:79) polypeptide,
a recombinant gene encoding an A. thaliana ATR2 (SEQ ID NO:51, SEQ D NO:87)
polypeptide, a recombinant gene encoding an O. sativa EUGT1 1 (SEQ D NO:86) polypeptide,
a recombinant gene encoding an SrKAHei (SEQ D NO: 18, SEQ ID NO:68) polypeptide, a
recombinant gene encoding an S. rebaudiana CPR8 (SEQ ID NO:24, SEQ D NO:28)
polypeptide, a recombinant gene encoding an S. rebaudiana UGT85C2 (SEQ ID NO:30)
polypeptide, a recombinant gene encoding an S. rebaudiana UGT76G1 (SEQ ID NO:2)
polypeptide, and a recombinant gene encoding an S. rebaudiana UGT91D2 variant,
UGT91D2e-b (SEQ ID NO:88), polypeptide accumulated steviol glycosides.
Example 3. Steviol Glycoside Production in Yeast Strains Expressing KO Genes
[00170] To determine whether increased levels of ent-kaurenoic acid improve steviol
glycoside production, the activity of KO genes from various species were analyzed. Putative
KO genes were identified using the NCBi Basic Local Alignment Sequence Search Tool
(BLAST). Genes encoding KO polypeptides were cloned and expressed the RebB-producing S.
cerevisiae strain described in Example 2 , which was modified to lack KO genes. Thus, RebB
was only accumulated upon expression of a functional KO.
[00171] Two KO polypeptides identified by the amino acid sequences set forth in SEQ D
NO:54 (nucleotide sequence set forth in SEQ ID NO:55) and SEQ ID NO:75 (nucleotide
sequences set forth in SEQ ID NO:56) were found to accumulate higher levels of RebB than
SrKOI (nucleotide sequence set forth in SEQ ID NO:59, amino acid sequences set forth in SEQ
ID NO:79) in the RebB-producing strain. RebB levels (µΜ/00 60ο) are shown in Figure 3 .
[00172] Expression of genes (SEQ ID NO:55 or SEQ ID NO:56) encoding KO polypeptides
in an S. cerevisiae steviol glycoside-producing strain also resulted in accumulation of ent-
kaurenoic acid (Figure 4). Expression of a gene encoding a codon-optimized KO polypeptide
(SEQ ID NO:57) and a gene encoding the KO polypeptide set forth in SEQ ID NO:70 also
resulted in accumulation of ent-kaurenoic acid. However, expression of SrKOI (SEQ ID NO:59,
SEQ ID NO:79) did not result in measurable levels of ent-kaurenoic acid. Thus, the KO
polypeptides encoded by nucleotide sequences set forth in SEQ ID NOs: 55-57 more efficiently
converted ent-kaurene, ent-kaurenol, and/or ent-kaurenal to ent-kaurenoic acid in S. cerevisiae,
as compared to the SrKOI polypeptide encoded by nucleotide sequence set forth in SEQ ID
NO:59.
Example 4. Steviol Glycoside Production in Yeast Strains Expressing KO Genes and
Further Overexpressing SrKAHel
[00173] Cloned KO genes were individually expressed in a steviol glycoside-producing S.
cerevisiae strain. The S. cerevisiae strain described in Example 2, which expresses SrKOI
(SEQ ID NO:59, SEQ ID NO:79), was modified to comprise overexpress SrKAHel (SEQ ID
NO:18, SEQ ID NO:68). The coding sequences of the KO genes tested, as well as their
corresponding amino acid sequences, are set forth in Table 2. The sequences set forth in SEQ
ID NOs: 55, 57, 58, 59, and 60 were codon-optimized for expression in S. cerevisiae.
Table 2 : KO Genes Expressed in Steviol Glycoside-Producing S. cerevisiae strain that
Further Overexpresses SrKAHel.
[00174] S. cerevisiae strains co-expressing any of the heterologous nucleic acids encoding a
KO enzyme of Table 2 and further overexprssing SrKAHel (SEQ ID NO:18, SEQ ID NO:68)
accumulated higher levels of steviol glycosides than the control S. cerevisiae strain (not
expressing a KO of Table 2) or a steviol glycoside-producing S. cerevisiae strain only
overexpressing SrKAHel , as shown in Figure 5. A steviol glycoside-producing S. cerevisiae
strain expressing a codon-optimized version of SEQ ID NO:56, identified herein as SEQ ID
NO:65, and overexpressing SrKAHel accumulated higher levels of steviol glycosides (RebA,
RebD, and RebM) than the steviol glycoside-producing S. cerevisiae strain co-expressing the
nucleic acid set forth in SEQ ID NO:56 and SrKAHel (Figure 6).
[001 75] Additionally, S, cerevisiae strains co-expressing a nucleic acid set forth in SEQ ID
NO:55, SEQ ID NO:56, SEQ ID NO:57, or SEQ ID NO:60 and further overexpressing SrKAHel
accumulated higher levels of glycosylated ent-kaurenoic acid than the control S. cerevisiae
strain not expressing a KO of Table 2 (Figure 7).
[00176] As well, S. cerevisiae strains co-expressing a nucleic acid set forth in SEQ ID
NO:55, SEQ ID NO:56, SEQ ID NO:57, SEQ ID NO:59, or SEQ ID NO:60 and further
overexpressing SrKAHel demonstrated improved metabolic conversion of intermediate
compound, ent-kaurenol, which, in turn, resulted in reduced accumulation of glycosylated ent-
kaurenol, relative to the control S. cerevisiae strain not expressing a KO of Table 2 or the steviol
glycoside-producing S. cerevisiae strain only overexpressing SrKAHel, as shown in Figure 8.
The control S. cerevisiae strain and the steviol glycoside-producing S. cerevisiae strain only
overexpressing SrKAHel each accumulated higher leveis of glycosylated ent-kaurenol than did
S. cerevisiae strains expressing a nucleic acid set forth in SEQ ID NO:55, SEQ ID NO:56, SEQ
ID NO:57, SEQ ID NO:59, or SEQ ID NO:60 and further overexpressing SrKAHel.
Example 5. Steviol Glycoside Production in Yeast Strains Expressing CPR Genes
[00177] Cloned CPR genes were individually expressed in a steviol glycoside-producing S.
cerevisiae strain. The steviol glycoside-producing S. cerevisiae strain described in Example 2,
which expresses S. rebaudiana CPR8 (SEQ ID NO:24, SEQ ID NO:28) and A. thaliana ATR2
(SEQ ID NO:51), was modified to co-express a nucleic acid encoding a CPR of Table 3. The
coding sequences of the CPR genes tested, as well as their corresponding amino acid
sequences, are set forth in Table 3.
[00178] As shown in Figure 9, expression of CPR1 (SEQ ID NO:61, SEQ ID NO:76) or of
CPR7 (SEQ ID NO:23, SEQ ID NO:69) in the steviol glycoside-producing S. cerevisiae strain
already expressing S. rebaudiana CPR8 (SEQ ID NO:24, SEQ ID NO:28) and A. thaliana ATR2
(SEQ ID NO:51) resulted in higher levels of RebM than those accumulated by the control steviol
glycoside-producing S. cerevisiae strain not expressing CPR1 or CPR7. As well, a steviol
glycoside-producing S. cerevisiae strain expressing the nucleic acid set forth in SEQ ID NO:62
and overexpressing SrKAHel (SEQ ID NO:18, SEQ ID NO:68) accumulated higher levels of
RebM than those accumulated by the control steviol glycoside-producing S. cerevisiae strain
that only overexpressed SrKAHel (Figure 10).
Example 6. Steviol Glycoside Production in Yeast Strains Co-Expressing KO and CPR
Genes
[00179] Steviol glycoside production was tested in the RebB-producing S. cerevisiae strain
described in Example 2, which was modified to co -express a KO gene of Table 4 and a CPR of
Table 5.
Table 4 : KO Genes Tested in Combination with CPR Genes.
Table 5: CPR Genes Tested in Combination with KO Genes.
[00180] As shown in Figure 12, co-expression of SrKOI (SEQ ID NO:59, SEQ ID NO:79) and
either of the CPR genes of Table 5 in the RebB-producing strain resulted in higher production of
13-SMG and RebB than co-expression of a nucleic acid set forth in SEQ ID NO:63 or SEQ ID
NO:64 and either of the cytochrome P450 genes of Table 5.
Example 7. Steviol Glycoside Production in Yeast Strains Expressing KAH Genes
[00181] Candidate KAH enzymes were cloned and expressed in an S. cerevisiae strain
engineered to accumulate 13-SMG. The 13-SMG-producing S. cerevisiae strain comprised a
recombinant gene encoding a Synechococcus sp. GGPPS7 polypeptide (SEQ ID NO:49), a
recombinant gene encoding a truncated Z. mays CDPS polypeptide (SEQ ID NO:37), a
recombinant gene encoding an A. thaliana KS polypeptide (SEQ ID NO:6), SrKOI (SEQ ID
NO:59, SEQ ID NO:79), CPR8 (SEQ ID NO:24, SEQ ID NO:28), the KO encoded by the
nucleotide sequence set forth in SEQ ID NO:56 (amino acid sequence set forth in SEQ ID
NO:75), and UGT85C2 (SEQ ID NO:30) chromosomally integrated in separate expression
cassettes (Figure 11B). The strain lacked SrKAHel (SEQ ID NO:18, SEQ ID NO:68); thus, 13-
SMG was only accumulated upon transformation of the S. cerevisiae strain with a functional
KAH (Figure 11B).
[001 82] Transformants were grown in SC-URA medium for 4 days and extracted with 1:1
with DMSO at 80°C for 10 min. The extracts were analyzed by LC-MS (method 2 of Example
1). S. cerevisiae transformed with the nucleic acid set forth in SEQ ID NO:80 accumulated 13-
SMG (Figure 11B). Thus, the protein encoded by SEQ ID NO:80, set forth in SEQ ID NO:82, is
a KAH.
[00183] The KAH encoded by the nucleotide sequence set forth in SEQ ID NO:80 was
codon-optimized for expression in yeast (SEQ ID NO:81) and expressed in the above-described
13-SMG-producing S. cerevisiae strain. Similar to expression of SrKAHel (SEQ ID NO:18) or
the KAH encoded by the nucleotide sequence set forth in SEQ ID NO:80, expression of the
codon-optimized nucleotide sequence set forth in SEQ ID NO:81 resulted in production of 13-
SMG plus rubusoside (Figure 13).
[00184] The KAHs encoded by the nucleotide sequence set forth in SEQ ID NO:80 and the
codon-optimized nucleotide sequence set forth in SEQ ID NO:81 were also individually
expressed in a steviol glycoside-producing strain, as described in Example 2 , which expresses
SrKAHel. Production of 13-SMG was increased upon overexpression of SrKAHel (SEQ ID
NO: 18), of the KAH encoded by the nucleotide sequence set forth in SEQ ID NO:80, or of the
KAH encoded by the codon-optimized nucleotide sequence set forth in SEQ ID NO:81, as
compared to a control strain not expressing the KAH encoded by the nucleotide sequence set
forth in SEQ ID NO:80, the KAH encoded by the codon-optimized nucleotide sequence set forth
in SEQ ID NO:81 , or overexpressing SrKAHel . See Table 6 . Expression of either the KAH
encoded by the nucleotide sequence set forth in SEQ ID NO:80 or the KAH encoded by the
codon-optimized nucleotide sequence set forth in SEQ ID NO:81 resulted in higher steviol
glycoside production ( 13-SMG + 1,2-bioside + rubusoside + RebB + RebA + RebD + RebM)
than either the controi strain or the S. cerevisiae strain overexpressing SrKAHel (SEQ ID
NO: 18). See Table 6.
Table 6: Quantification of Steviol Glycosides Accumulated by Yeast Expressing KAH
Genes.
Example 8. Steviol Glycoside Production in Yeast Strain Expressing KAH Gene of the
CYP72A219 family
[001 85] A nucleic acid of SEQ ID NO:90, which was codon-optimized for expression in S.
cerevisiae and encodes the polypeptide of SEQ ID NO:91 , was cloned and expressed in an S.
cerevisiae strain described in Example 7, which was engineered to accumulate 13-SMG. The
13-SMG-producing S. cerevisiae strain comprised a recombinant gene encoding a
Synechococcus sp. GGPPS7 polypeptide (SEQ ID NO:49), a recombinant gene encoding a
truncated Z. mays CDPS polypeptide (SEQ ID NO:37), a recombinant gene encoding an A.
thaliana KS polypeptide (SEQ ID NO:6), SrKOI (SEQ ID NO:59, SEQ ID NO:79), CPR8 (SEQ
ID NO:24, SEQ ID NO:28), the KO encoded by the nucleotide sequence set forth in SEQ ID
NO:56 (amino acid sequence set forth in SEQ ID NO:75), and UGT85C2 (SEQ ID NO:30)
chromosoma!ly integrated in separate expression cassettes.
[00186] Transformants were grown in SC-URA medium for 4 days and extracted 1:1 with
DMSO at 80°C for 10 min. The extracts were analyzed by LC-MS (method 2 of Example 1). S.
cerevisiae transformed with the nucleic acid set forth in SEQ ID NO:90 accumulated 13-SMG as
well as rubusoside (Table 7). Thus, the protein encoded by the nucleic acid sequence of SEQ
ID NO:90, set forth in SEQ ID NO:91 , is a KAH.
Table 7: Quantification of Steviol Glycosides Accumulated by Yeast Expressing the KAH
encoded by the Nucleotide Sequence Set Forth in SEQ ID NO:90 (Amino Acid
Sequence Set Forth in SEQ ID NO:91).
Example 9. Determination of CPR1 and CPR12 Activity
[00187] Activity of CPR1 and CPR12 were measured using an in vitro microsomal assay.
Microsomes were prepared by a modified version of the method taught by Pompon et a/., "Yeast
expression of animal and plant P450s in optimized redox environments," Methods Enzymol.
272:51-64 (1996). S. cerevisiae cells were sedimented for 10 min at 4°C. The pellets were
washed with 10 mL TEK buffer (50 mM Tris-HCI (pH 7.5), 1 mM EDTA, 100 mM KCI.) The cells
were sedimented again for 10 min at 4°C, and the pellets were resuspended in 1-3 mL of TES2
buffer (50 mM Tri-HCI (pH 7.5) 1 mM EDTA, 600 mM sorbitol). Glass beads (425-600 microns)
were added to the samples, and the cells were broken vigorously by shaking and vortexing for 5
min at 4°C. The supernatant was collected, and the beads were washed several times with
TES2 buffer. The washes were combined with the supernatant, and the samples were
centrifuged for 15 min at 4°C to remove unbroken cells and glass beads. Samples were then
ultracentrifuged for 1 h at 4°C. The pellets were washed twice with TES buffer (50 mM Tris-HCI
(pH 7.5), 1 mM EDTA, 600 mM sorbitol, 1% (w/V) BSA, 5 mM DTT), and once with TEG buffer
(50 mM Tris-HCI (pH 7.5), 1 mM EDTA, 30% (V/V) glycerol). The samples were resuspended in
1-3 mL TEG, and the pellets were homogenized.
[001 88] Wild-type control microsomal protein was prepared as described above from wild-
type S. cerevisiae cells that did not comprise a heterologous KAH or CPR. Microsomal protein
was also prepared from S. cerevisiae cells expressing i) SrKAHel (SEQ ID NO:18, SEQ ID
NO:68), ii) SrKAHel (SEQ ID NO:18, SEQ ID NO:68) and CPR1 (SEQ ID NO:61, SEQ ID
NO:76), or iii) SrKAHel (SEQ ID NO:18, SEQ ID NO:68) and CPR12 (SEQ ID NO:97, SEQ ID
NO:98) from a genetic construct integrated at the chromosome level. Microsomal protein from a
steviol glycoside-producing strain was prepared from S. cerevisiae cells expressing the genes
described in Example 2 and additionally comprising codon-optimized CPR1 from S. rebaudiana
(SEQ ID NO:61 corresponding to amino acid sequence SEQ ID NO:76) as well as the KO
encoded by SEQ ID NO:75).
[00189] CPR1 and CPR12 activities were first determined using a cytochrome C reductase
assay kit (Sigma-Aldrich; CY0100-1KT) to measure the ability of CPR1 or CPR12 to reduce
cytochrome C in the presence of NADPH in vitro. Reduction of cytochrome C resulted in an
increase in absorbance at 550 nm, which could quantified spectrophotometrically. Working
solution was prepared by adding 9 mg cytochrome C to 20 mt_ assay buffer, and solution was
stored at 25°C until use. NADPH was diluted in H20 to a concentration of 0.85 mg/mL. Final
reaction volumes were 1. 1 mL (950µL working solution (0.43 mg cytochrome C), 28 µL. enzyme
dilution buffer, 100 µL NADPH solution (0.085 mg NADPH), 20µL cytochrome C oxidase
inhibitor, 2µL microsomal protein.) Blank samples did not comprise microsomal protein and
were prepared with 950µL working solution (0.43 mg cytochrome C), 30µL enzyme dilution
buffer, 100 µL NADPH solution (0.085 mg NADPH), and 20 µL. cytochrome C oxidase inhibitor.
The spectrophotometer was blanked with all components added to the reactions except for
NADPH. The enzymatic reactions were initiated by addition of NADPH, the samples were
thoroughly mixed by pipetting, and absorbance was measured at 550 nm for 70 s with 10 s
intervals between reads. Two independent rate measurements were taken for each microsomal
preparation, and rates were averaged for calculation of specific activity. After the reactions
were completed, results were normalized to protein concentration, which was measured using a
standard BCA assay (Thermo Scientific).
[00190] Units/mL was calculated using the following equation, where ∆A550/min represents
the change in absorbance at 550 nm during the absorbance reading period, 1.1 represents the
reaction volume in mL, and 2 1 .1 represents the extinction coefficient for reduced cytochrome c:
Units/mL = (∆A550/min x dilution factor x 1.1 ) / (21.1 x enzyme volume)
[00191] The units/mL value of each sample was divided by its respective microsomal protein
concentrations to calculate CPR activity in units/mg. Figure 14 shows the activity
measurements of the i) SrKAHel (SEQ ID NO:18, SEQ ID NO:68), ii) SrKAHel (SEQ ID NO:18,
SEQ ID NO:68) and CPR1 (SEQ ID NO:61, SEQ ID NO:76), and iii) SrKAHel (SEQ ID NO: 18,
SEQ ID NO:68) and CPR12 (SEQ ID NO:97, SEQ ID NO:98) microsomal samples.
[001 92] The microsomal preparation from the wild-type control showed only minimal CPR
activity, reflecting the low activity of native NCP1 (YHR042W). Likewise, the microsomal
preparation from a yeast strain overexpressing KAHel did not demonstrate an increase in CPR
activity. In contrast, microsomal preparation from strains expressing SrKAHel (SEQ ID NO:18,
SEQ ID NO:68) and CPR1 (SEQ ID NO:61, SEQ ID NO:76) or SrKAHel (SEQ ID NO:18, SEQ
ID NO:68) and CPR12 (SEQ ID NO:97, SEQ ID NO:98) demonstrated high CPR activity, with 7-
and 14-fold higher activity, respectively, compared to the negative control (Figure 14).
[00193] In a separate experiment, formation of steviol and consumption of ent-kaurenoic acid
in microsomes, as prepared above, were measured. 33 µΜ ent-kaurenoic acid, 10 mM NADPH,
and 10 µL of microsomal protein in 50 mM phosphate buffer (pH 7.5) were incubated for 30 min
at 30°C in a total reaction volume of 100 µL. Control reactions were extracted immediately after
addition of all the reaction components, which were mixed on ice and aliquoted prior to
incubation. Steviol and ent-kaurenoic acid ievels were quantified using the second LC-MS
procedure described in Example 1. For steviol quantification, the microsomal reactions were
extracted with DMSO (1:1) at 80°C for 10 min and submitted for LC-MS analysis after
centrifugation. For ent-kaurenoic acid quantification the microsomes reactions were extracted
with acetonitrile 1:4 (20% microsomal reaction and 80% acetonitrile) at 80°C for 10 min and
after centrifugation submitted for LC-MS analysis. The AUC values obtained for the ent-
kaurenoic acid measurements were converted to concentrations using a standard curve.
[00194] As shown in Figure 15A, microsomal protein prepared from an S. cerevisiae strain
expressing SrKAHel (SEQ ID NO: 18, SEQ ID NO:68) and either CPR1 (SEQ ID NO:61, SEQ
ID NO:76) or CPR12 (SEQ ID NO:97, SEQ ID NO:98) converted ent-kaurenoic acid to steviol
during the 30 minute incubation period. The steviol level shown in Figure 15A for the steviol-
glycoside-producing strain control (extracted immediately with no 30 min incubation period)
corresponds to steviol that was accumulated by the strain prior to microsomal preparation and
that had co-purified with the microsomes. As shown in Figure 15B, ent-kaurenoic acid Ievels
decreased upon incubation with microsomal protein prepared from S. cerevisiae strains
expressing SrKAHel (SEQ ID NO:18, SEQ ID NO:68) alone or in combination with CPR1 (SEQ
ID NO:61, SEQ ID NO:76) or CPR12 (SEQ ID NO:97, SEQ ID NO:98). The increased ent-
kaurenoic acid Ievels shown in Figure 15B for the steviol glycoside-producing strain microsomal
sample incubated for 30 min corresponds to ent-kaurenoic acid that was accumulated by the
strain prior to microsomal preparation and to ent-kaurenoic acid accumulated from ent-kaurene
that had co-purified with the microsomes. The levels of ent-kaurenoic acid shown in Figure 15B
were corrected for the dilution factor used.
Example 10. Steviol Glycoside Production in S. cerevisiae strains comprising Fusion
Constructs between a KO and a P450 Reductase Domain
[00195] CYP102A1 (also referred to as P450BM3 ; SEQ ID NO:1 15, SEQ ID NO:1 16) is a
catalytically self-sufficient soluble enzyme from Bacillus megatarium. See, e.g., Whitehouse et
ai, 2012, Chem Soc Rev. 4 1(3): 121 8-60. Two domains are present in the CYP102A1
polypeptide chain: a P450 heme domain (BMP) and an NADPH-dependent P450
oxidoreductase domain (BMR). CYP102A1 utilizes nearly 100% of the reducing power of
NADPH to produce a monooxygenated product. See, e.g., Yuan et ai, 2009, Biochemistry
48(38):9140-6.
[00196] The BMR domain of CYP102A1 ("BMR"; codon-optimized nucleotide sequence set
forth in SEQ ID NO:1 17, SEQ ID NO:1 18) was fused to SrKOi (SEQ ID NO:59, SEQ ID NO:79)
or a KO encoded by the nucleotide sequence set forth in SEQ ID NO:65 (amino acid sequence
set forth in SEQ ID NO:75) with a linker (SEQ ID NO:121, SEQ ID NO:122), as described in
Dodhia et ai, 2006, J Biol Inorg Chem. 11(7):903-16. A wild-type version of the BMR domain of
CYP102A1, as well as a W1046A mutant of the BMR domain (SEQ ID NO: 119, SEQ ID
NO:120), which has been found to switch the cofactor specificity of CYP102A1 from NADPH to
NADH, were used. See, Girvan et a/., 2011, Arch Biochem Biophys. 507(1 ):75-85. SrKOi
(SEQ ID NO:59, SEQ ID NO:79) and the KO encoded by the nucleotide sequence set forth in
SEQ ID NO:65 were also truncated prior to fusion with the BMR domain of CYP102A1; these
truncations were predicted by bioinformatics to result in loss of membrane anchors of the KO
genes and in cytosolic versions of the KO-BMR fusion constructs. The KO-BMR fusion
constructs analyzed are shown in Table 8 .
Table 8: KO-BMR fusion constructs and sequences.
[00197] The KO-BMR fusion constructs were cloned and transformed in the RebB-producing
strain described in Example 2, which was modified to not comprise any additional KO genes.
Thus, steviol glycosides, including 13-SMG, 1,2-bioside, and RebB, were only accumulated
upon expression of a functional KO. Three scrapes ( 1 µL. loop of cells) from each
transformation plate were resuspended in 200 µ Ι nanopure H2O. 70 wereµLthen transferred to
1 mL SC-URA in a 96 deep well plate and incubated at 30°C for 5 days at 400 rpm. Biological
triplicates were analyzed by LC-MS (method 2 of Example 1) to measure 13-SMG, 1,2-bioside,
and RebB levels, and single samples were analyzed by LC-UV to measure ent-kaurene and
ent-kaurenoic acid levels.
[00198] For LC-MS, 50 µLsamples were mixed with 50 µL 100% DMSO and heated to 80 C
for 10 min. Subsequently, the samples were spun down at 4000 RCF for 10 min, and 85 µL. of
the resulting supernatant was transferred to an LC-MS plate. The LC-MS results were
normalized by OD600 of individual cultures, which was measured by a Wallac, 2104 EnVision
(Perkin Elmer) plate reader.
[00199] LC-UV was conducted with an Agilent 1290 instrument comprising a variable
wavelength detector (VWD), a thermostatted column compartment (TCC), an autosampler, an
autosampler cooling unit, and a binary pump and using SB-C18 rapid resolution high definition
(RRHD) 2.1 mm x 300 mm, 1.8 pm analytical columns (two 150 mm columns in series; column
temperature of 65°C). Steviol glycosides and steviol glycoside precursors were separated by a
reversed phase C18 column followed by detection by UV absorbance at 210 mm.
Quantification of steviol glycosides was done by comparing the peak area of each analyte to
standards of RebA and applying a correction factor for species with differing molar
absorptivities. Quantification of steviol glycoside precursors (such as kaurenoic acid, kaurenal,
kaurenol, ent-kaurene, and geranylgeraniol) was done by comparing the peak area of each
analyte to standards of kaurenoic acid and applying a correction factor for species with differing
molar absorptivities. For LC-UV, 0.5 rriL cultures were spun down, the supernatant was
removed, and the wet weight of the pellets was calculated. The LC-UV results were normalized
by pellet wet weight.
[00200] As shown in Figures 16B and 16D, the S. cerevisiae strain transformed with empty
plasmid accumulated ent-kaurene. Transformation with a plasmid comprising SrKOI (SEQ ID
NO:59, SEQ ID NO:79) or with a plasmid comprising the KO gene having the nucleotide
sequence set forth in SEQ ID NO:65 resulted in accumulation of 13-SMG, 1,2-bioside, and
RebB (Figures 16A and 186C).
[00201] Expression of full-length SrKOI -BMR fusion constructs (wild type or W 1046A mutant
BMR; SEQ ID NOs:99-102), resulted in an increase in ent-kaurenoic acid, 13-SMG, and RebB,
compared to expression of SrKOI (SEQ ID NO:59, SEQ ID NO:79). See Figures 16A and 16B.
Expression of truncated SrKOI -BMR fusion constructs (wild type or W1046A mutant BMR; SEQ
ID NOs: 103-1 06) resulted in an increase in ent-kaurenoic acid, compared to expression of
SrKOI (SEQ ID NO:59, SEQ ID NO:79) (Figure 16B). Although the truncated SrKOI -BMR
fusion constructs also increased steviol glycoside production, glycosyiation activity was higher
for the full-length SrKOI-BMR fusion constructs than for the truncated SrKOI -BMR fusion
constructs (Figure 16A).
[00202] Expression of a fusion construct comprising the KO encoded by the nucleotide
sequence set forth in SEQ ID NO:65 and the wild type BMR (SEQ ID NO:107, SEQ ID NO: 108)
resulted in greater conversion of ent-kaurenoic acid to 13-SMG, compared to the KO encoded
by the nucleotide sequence set forth in SEQ ID NO:65 (Figure 16C). Expression of a fusion
construct comprising the KO encoded by the nucleotide sequence set forth in SEQ ID NO:65
and the W 1046A mutant BMR (SEQ ID NO: 109, SEQ ID NO:1 10) resulted in decreases in ent-
kaurenoic acid levels but glycosyiation activity similar to that of the KO encoded by the
nucleotide sequence set forth in SEQ ID NO:65 (Figure 16C).
Example 11. Evaluation of Steviol Glycoside Pathway in S, cerevisiae Strain Comprising
ICE2
[00203] ICE2 is an endoplasmic reticulum (ER) membrane protein involved in mechanisms
such as ER zinc homeostasis and cytochrome P450 stability and/or activity. See, e.g., Estrada
de Martin et al., 2005, J Cell Sci. 118(Pt 1):65-77 and Emmerstorfer et al., 2015, Biotechnol J.
10(4):623-35. ICE2 (SEQ ID NO:1 13, SEQ ID NO:1 14) was cloned and overexpressed in a
steviol glycoside-producing S. cerevisiae strain comprising a recombinant gene encoding a
Synechococcus sp. GGPPS polypeptide (SEQ ID NO:49), a recombinant gene encoding a
truncated Z. mays CDPS polypeptide (SEQ ID NO:37), a recombinant gene encoding an A.
thaliana KS polypeptide (SEQ ID NO:6), a recombinant gene encoding a recombinant S.
rebaudiana KO polypeptide (SEQ ID NO:59, SEQ ID NO:79), a recombinant gene encoding an
A. thaliana ATR2 polypeptide (SEQ ID NO:51 , SEQ ID NO:87), a recombinant gene encoding
an SrKAHel (SEQ ID NO:18, SEQ ID NO:68) polypeptide, a recombinant gene encoding an S.
rebaudiana CPR8 polypeptide (SEQ ID NO:24, SEQ ID NO:28), a recombinant KAH gene
encoded by the nucleotide sequence set forth in SEQ ID NO:81 (corresponding to the amino
acid sequence set forth in SEQ ID NO:82), a recombinant KO gene encoded by the nucleotide
sequence set forth in SEQ ID NO:56 (corresponding to the amino acid sequence set forth in
SEQ ID NO:75), a recombinant KO gene encoded by the nucleotide sequence set forth in SEQ
ID NO:65 (corresponding to the amino acid sequence set forth in SEQ ID NO:75), a
recombinant gene encoding a UGT76G1 (SEQ ID NO:83) polypeptide, a recombinant gene
encoding an S, rebaudiana UGT85C2 polypeptide (SEQ ID NO:30), a recombinant gene
encoding an S. rebaudiana UGT74G1 polypeptide (SEQ ID NO:29), a recombinant gene
encoding an EUGT11 (SEQ ID NO:86) polypeptide, a recombinant gene encoding a UGT91 D2e
(SEQ ID NO;84) polypeptide, and a recombinant gene encoding a CPR1 (SEQ ID NO:61, SEQ
ID NO:76) polypeptide. Overexpression was performed by integration using the USER cloning
system; see, e.g., Nour-Eldin et al., 2010, Methods Mol Biol. 643:185-200. Table 9 shows
additional recombinant genes (ICE2 and/or CPR12) expressed in the above-described strain.
The control strain did not comprise recombinant genes encoding ICE2 (SEQ ID NO:1 13, SEQ
ID NO: 114) or CPR12 (SEQ ID NO:97, SEQ ID NO:98) polypeptides.
Table 9: ICE2 steviol glycoside-producing strains.
[00204] Fed-batch fermentation was carried out aerobically in 2 L fermenters at 30°C with an
approximate 16 h growth phase in minimal medium comprising glucose, ammonium sulfate,
trace metals, vitamins, salts, and buffer followed by an approximate 110 h feeding phase with a
glucose-comprising defined feed medium. A pH near 6.0 and glucose-limiting conditions were
maintained. Whole culture samples (without cell removal) were analysed by the LC-UV method
of Example 10 to determine levels of steviol glycosides and steviol pathway intermediates.
[00205] The following values were calculated based upon the measured levels of steviol
glycosides and steviol glycoside precursors. "Total Flux" was calculated as a sum (in g/L RebD
equivalents) of measured RebA, RebB, RebD, RebE, RebM, 13-SMG, rubusoside, steviol-1,2-
bioside, di-glycosylated steviol, tri-glycosylated steviol, tetra-glycosylated steviol, penta-
glycosytated steviol, hexa-glycosylated steviol, hepta-glycosylated steviol, copalol, ent-
kaurenoic acid, glycosylated ent-kaurenoic acid, glycosylated ent-kaurenol, ent-kaurena!,
geranylgeraniol, ent-kaurenal, and ent-kaurene levels. "Pre-steviol glycoside/flux" was
calculated as (("total flux" - (geranylgeraniol + copalol + ent-kaurene + glycosylated ent-
kaurenol + ent-kaurenol + ent-kaurenal + ent-kaurenoic acid + glycosylated ent-kaurenoic acid) /
"total flux"). "KAH step/flux" was calculated as ((ent-kaurenoic acid + glycosylated ent-
kaurenoic acid) / "total flux"). "KO step/flux" was calculated as ((ent-kaurene + glycosylated ent-
kaurenol + ent-kaurenol + ent-kaurenal) / "total flux").
[00206] The pre-steviol glycoside/flux, KO step/flux, and KAH step/flux values are shown in
Table 10 below. Decreased amounts of ent-kaurene, ent-kaurenol, ent-kaurenal, glycosylated
ent-kaurenol and increased amounts of ent-kaurenoic acid and glycosylated ent-kaurenoic acid
were observed in the strains comprising ICE2, as compared to the control steviol glycoside-
producing strain. These effects were stronger in the presence of CPR1 and/or CPR12 (Table
10). Overexpression of two copies of ICE2 (ICE2 strain B) resulted decreased ent-kaurene, ent-
kaurenol, ent-kaurenal, and ent-kaurenol glycoside levels and increased steviol glycoside levels,
compared to the control strain, ICE2 strain A, or ICE2 strain C (Table 10). Steviol glycoside
levels increased most in the steviol glycoside-producing strain comprising two copies of ICE2.
Thus, ICE2 was found to improve cytochrome P450 function.
Table 10: Pre-steviol glycoside/flux, KO step/flux, and KAH step/flux values for steviol
glycoside-producing strains comprising ICE2.
Example 12. Steviol Glycoside Production by Fermentation of S. cerevisiae strain
comprising CPR1 and CPR12
[00207] Steviol glycoside-producing S, cerevisiae strains comprising a recombinant gene
encoding a Synechococcus sp. GGPPS polypeptide (SEQ ID NO:49), a recombinant gene
encoding a truncated Z. mays CDPS polypeptide (SEQ ID NO:37), a recombinant gene
encoding an A. thaliana KS polypeptide (SEQ ID NO:6), a recombinant gene encoding a
recombinant S. rebaudiana KO polypeptide (SEQ ID NO:59, SEQ ID NO:79), a recombinant
gene encoding an A. thaliana ATR2 polypeptide (SEQ ID NO:51, SEQ ID NO:87), a
recombinant gene encoding an SrKAHei (SEQ ID NO:18, SEQ ID NO:68) polypeptide, a
recombinant gene encoding an S. rebaudiana CPR8 polypeptide (SEQ ID NO:24, SEQ ID
NO:28), a recombinant gene encoding a CPR1 (SEQ ID NO:61, SEQ ID NO:76) polypeptide, a
recombinant gene encoding an SrKAHei (SEQ ID NO:18, SEQ ID NO:68) polypeptide, a
recombinant KO gene encoded by the nucleotide sequence set forth in SEQ ID NO:56
(corresponding to the amino acid sequence set forth in SEQ ID NO:75), a recombinant gene
encoding a UGT76G1 (SEQ ID NO:83) polypeptide, a recombinant gene encoding an S.
rebaudiana UGT85C2 (SEQ ID NO:30) polypeptide, a recombinant gene encoding an S.
rebaudiana UGT74G1 (SEQ ID NO:29) polypeptide, a recombinant gene encoding a
UGT91D2e-b polypeptide (SEQ ID NO:88), and a recombinant gene encoding an EUGT1 1
(SEQ ID NO:86) polypeptide, as well as the recombinant genes shown in Table 11, which were
genomica!ly integrated into the strains, were cultivated by fermentation. Levels of steviol
glycosides and steviol glycoside precursors were measured by LC-UV as described in Example
11. The pre-KO/flux, pre-KAH/flux, pre-steviol giycoside/flux values were calculated as
described in Example 11.
[00208] The pre-steviol glycoside/flux, KO step/flux, and KAH step/flux values are shown in
Table 12 below. In the strain comprising the KO encoded by nucleotide sequence set forth in
SEQ ID NO:56 (strain A), lower accumulation of ent-kaurene, ent-kaurenol, ent-kaurnal, and
ent-kaurenol glycosides resulted. Higher levels of ent-kaurenoic acid and steviol glycosides
were also measured, as compared to the control strain. In the strain comprising the KAH
encoded by nucleotide sequence set forth in SEQ ID NO:80, the KO encoded by nucleotide
sequence set forth in SEQ ID NO:56 (corresponding to amino acid sequence set forth in SEQ ID
NO:75), and the KO encoded by nucleotide sequence set forth in SEQ ID NO:65 (strain B), ent-
kaurene, ent-kaurenol, ent-kaurenal, ent-kaurenol glycosides, and ent-kaurenoic acid
accumulation decreased and accumulation of steviol glycosides increased, as compared to the
control strain. In the strain comprising CPR12 (SEQ ID NO:97, SEQ ID NO:98), the KAH
encoded by nucleotide sequence set forth in SEQ ID NO:80, and the KO encoded by nucleotide
sequence set forth in SEQ ID NO:56 (strain C), ent-kaurenol, ent-kaurenal, ent-kaurenol
glycosides, and ent-kaurenoic acid accumulation decreased and accumulation of steviol
glycosides increased, as compared to the control. See Table 12. Thus, CPR12 was found to
be a reductase protein that improves KAH and/or KO activity.
[00209] Having described the invention in detail and by reference to specific embodiments
thereof, it will be apparent that modifications and variations are possible without departing from
the scope of the invention defined in the appended claims. More specifically, although some
aspects of the present invention are identified herein as particularly advantageous, it is
contemplated that the present invention is not necessarily limited to these particular aspects of
the invention.











































WHAT IS CLAIMED IS:
. A recombinant host comprising one or more of:
(a) a gene encoding an ent-kaurene oxidase (KO) polypeptide;
(b) a gene encoding a cytochrome P450 reductase (CPR) polypeptide;
and/or
(c) a gene encoding an ent-kaurenoic acid hydroxylase (KAH) polypeptide;
wherein at least one of the genes is a recombinant gene; and
wherein the recombinant host is capable of producing a steviol glycoside
precursor.
2 . A recombinant host comprising:
(a) a gene encoding a geranylgeranyi diphosphate synthase (GGPPS)
polypeptide;
(b) a gene encoding an ent-copalyi diphosphate synthase (CDPS)
polypeptide;
(c) a gene encoding an ent-kaurene synthase (KS) polypeptide
(d) a gene encoding an ent-kaurene oxidase (KO) polypeptide;
(e) a gene encoding a cytochrome P450 reductase (CPR) polypeptide; and
(f) a gene encoding an ent-kaurenoic acid hydroxylase (KAH) polypeptide;
wherein at least one of the genes is a recombinant gene; and
wherein the recombinant host is capable of producing steviol.
3 . The recombinant host of claims 1 or 2, wherein:
(a) the KO polypeptide comprises a KO polypeptide having at least 60% identity to
an amino acid sequence set forth in SEQ ID NO:72 or SEQ D NO:75; at least
65% identity to an amino acid sequence set forth in SEQ D NO:54; at least 70%
identity to an amino acid sequence set forth in SED D NO: 70, SEQ D NO:71, or
SEQ ID NO:79; at least 40% identity to an amino acid sequence set forth in SEQ
ID NO:77; or at least 50% identity to an amino acid sequence set forth in SEQ ID
NO:78;
(b) the CPR polypeptide comprises a CPR polypeptide having at least 70% identity
to an amino acid sequences set forth in SEQ ID NO:69, SEQ ID NO:74, SEQ ID
NO:76, or SEQ ID NO:87; at least 80% identity to an amino acid sequence set
forth in SEQ ID NO:73; at least 85% identity to an amino acid sequence set forth
in SEQ ID NO:22; at least 65% identity to an amino acid sequence set forth in
SEQ ID NO:28; or at least 50% identity to an amino acid sequence set forth in
SEQ ID NO:98; and/or
(c) the KAH polypeptide comprises a KAH polypeptide having at least 40% identity
to an amino acid sequence set forth in SEQ ID NO:82; at least 50% identity to an
amino acid sequence set forth in SEQ ID NO:91 ; or at least 60% identity to an
amino acid sequence set forth in SEQ ID NO:68.
A recombinant host comprising one or more of:4 .
(a) a gene encoding a KO polypeptide having at least 60% identity to an
amino acid sequence set forth in SEQ ID NO:75;
(b) a gene encoding a KAH polypeptide having at least 40% identity to an
amino acid sequence set forth in SEQ ID NO:82; and/or
(c) a gene encoding a CPR polypeptide having at least 50% identity to an
amino acid sequence set forth in SEQ ID NO:98;
wherein at least one of the genes is a recombinant gene; and
wherein the recombinant host is capable of producing a steviol glycoside
precursor.
A recombinant host comprising one or more of:
.
(a) a gene encoding a KO polypeptide having at least 70% identity to an
amino acid sequence set forth in SEQ ID NO:70;
(b) a gene encoding a KAH polypeptide having at least 40% identity to an
amino acid sequence set forth in SEQ ID NO:82; and/or
(c) a gene encoding a CPR polypeptide having at least 50% identity to an
amino acid sequence set forth in SEQ ID NO:98;
wherein at least one of the genes is a recombinant gene; and
wherein the recombinant host is capable of producing a steviol glycoside
precursor.
6. The recombinant host of claim 4 or 5, wherein the host further comprises a gene
encoding a KO polypeptide having at least 65% identity to an amino acid sequence set
forth in SEQ ID NO:54.
7 . The recombinant host of any one of claims 4-6, wherein the host further comprises a
gene encoding a KAH polypeptide having at least 60% identity to an amino acid
sequence set forth in SEQ ID NO:68.
8. The recombinant host of any one of claims 4-7, wherein the host further comprises a
gene encoding a KO polypeptide having at least 70% identity to an amino acid sequence
set forth in SEQ ID NO:79.
9 . The recombinant host of any one of claims 1 or 3-8, wherein the host further comprises
one or more of:
(a) a gene encoding a geranylgeranyl diphosphate synthase (GGPPS)
polypeptide;
(b) a gene encoding an ent-copalyl diphosphate synthase (CDPS)
polypeptide; and/or
(c) a gene encoding an ent-kaurene synthase (KS) polypeptide;
wherein at least one of the genes is a recombinant gene; and
wherein the recombinant host is capable of producing a steviol glycoside
precursor.
10. The recombinant host of claim 9, wherein:
(a) the GGPPS polypeptide comprises a polypeptide having at least 70%
identity to an amino acid sequence set forth in SEQ ID NO:49;
(b) the CDPS polypeptide comprises a polypeptide having at least 70%
identity to an amino acid sequence set forth in SEQ ID NO:37; and/or
(c) the KS polypeptide comprises a polypeptide having at least 40% identity
to an amino acid sequence set forth in SEQ ID NO:6.
11. The recombinant host of claims 1-10, wherein the host further comprises a gene
encoding an endoplasmic reticulum membrane polypeptide.
12. The recombinant host of claim 11, wherein the endoplasmic reticulum membrane
polypeptide comprises an Inheritance of cortical ER protein 2 (ICE2) polypeptide having
at least 50% identity to the amino acid sequence set forth in SEQ ID NO:114.
13. The recombinant host of any one of claim 1-10, wherein the KO polypeptide is a fusion
construct.
14. The recombinant host of claim 13, wherein the fusion construct comprises a polypeptide
having at least 60% identity to an amino acid sequence set forth in SEQ ID NO:1 18 or
SEQ ID NO:120.
15. The recombinant host of claim 13 or claim 14, wherein the fusion construct has at least
50% identity to an amino acid sequence set forth in SEQ ID NO: 100, SEQ ID NO: 102,
SEQ ID NO: 104, SEQ ID NO: 106, SEQ ID NO:108, SEQ ID NO:1 10, or SEQ ID NO:1 12.
The recombinant host of any one of claims 1-15, wherein the host further comprises one16.
or more of:
(a) a gene encoding a UGT85C polypeptide;
(b) a gene encoding a UGT76G polypeptide;
(c) a gene encoding a UGT74G1 polypeptide;
(d) a gene encoding a UGT91 D2 functional homolog polypeptide; and/or
(e) a gene encoding an EUGT11 polypeptide;
wherein at least one of the genes is a recombinant gene; and
wherein the host is capable of producing a steviol glycoside.
17. The recombinant host of claim 16, wherein:
(a) the UGT85C2 polypeptide comprises a polypeptide having at least 55%
identity to an amino acid sequence set forth in SEQ ID NO:30;
(b) the UGT76G1 polypeptide comprises a polypeptide having at least 50%
identity to an amino acid sequence set forth in SEQ ID NO:83;
(c) the UGT74G1 polypeptide comprises a polypeptide having at least 55%
identity to an amino acid sequence set forth in SEQ ID NO:29;
(d) the UGT91 D2 functional homolog polypeptide comprises a UGT91D2
polypeptide having 90% or greater identity to the amino acid sequence
set forth in SEQ ID NO:84 or a UGT91D2e-b polypeptide having 90% or
greater identity to the amino acid sequence set forth in SEQ ID NO:88;
and/or
(e) the EUGT1 1 polypeptide comprises a polypeptide having at least 65%
identity to an amino acid sequence set forth in SEQ ID NO:86.
1 8 . The recombinant host of any one of claims 1-17, wherein the recombinant host
comprises a plant cell, a mammalian cell, an insect cell, a fungal cell, or a bacterial cell.
19. The recombinant host of claim 18, wherein the bacterial cell comprises Escherichia
bacteria cells, Lactobacillus bacteria cells, Lactococcus bacteria cells, Cornebacterium
bacteria cells, Acetobacter bacteria cells, Acinetobacter bacteria cells, or Pseudomonas
bacterial cells.
20. The recombinant host of claim 18, wherein the fungal cell comprises a yeast cell.
The recombinant host of claim 20, wherein the yeast cell is a cell from Saccharomyces2 1 .
cerevisiae, Schizosaccharomyces pombe, Yarrowia lipolytica, Candida glabrata, Ashbya
gossypii, Cyberlindnera jadinii, Pichia pastoris, Kluyveromyces lactis, Hansenula
polymorpha, Candida boidinii, Arxula adeninivorans, Xanthophyllomyces dendrorhous,
or Candida albicans species.
22. The recombinant host of claim 21, wherein the yeast cell is a Saccharomycete.
23. The recombinant host of claim 22, wherein the yeast cell is a cell from the
Saccharomyces cerevisiae species.
24. A method of producing a steviol glycoside or a steviol glycoside precursor, comprising:
(a) growing the recombinant host of any one of claims 1-23 in a culture
medium, under conditions in which any of the genes disclosed in any one
of claims 1-23 are expressed;
wherein the steviol glycoside or the steviol glycoside precursor is
synthesized by said host; and/or
(b) optionally quantifying the steviol glycoside or the steviol glycoside
precursor; and/or
(c) optionally isolating the steviol glycoside or the steviol glycoside precursor.
25. The method of claim 24, wherein the steviol glycoside comprises steviol-1 3-O-glucoside
(13-SMG), steviol-1 ,2-bioside, steviol-1, 3-bioside, steviol-1 9-O-glucoside (19-SMG),
stevioside, 1,3-stevioside, rubusoside, Rebaudioside A (RebA), Rebaudioside B (RebB),
Rebaudioside C (RebC), Rebaudioside D (RebD), Rebaudioside E (RebE),
Rebaudioside F (RebF), Rebaudioside M (RebM), Rebaudioside Q (RebQ),
Rebaudioside I (Rebl), dulcoside A, di-glycosylated steviol, tri-glycosylated steviol, tetra-
glycosylated steviol, penta-glycosylated steviol, hexa-glycosylated steviol, hepta-
glycosylated steviol, or isomers thereof.
26. The steviol glycoside or the steviol glycoside precursor produced by the recombinant
host of any one of claims 1-23 or the method of claim 24 or claim 25, wherein the steviol
glycoside or steviol glycoside precursor accumulates to a detectable concentration when
cultured under said conditions.
27. A steviol glycoside composition produced by the host of any one of claims 1-23 or the
method of claim 24 or claim 25, wherein the composition has an undetectable
concentration of stevia plant-derived contaminants.
28. A steviol glycoside composition produced by the host of any one of claims 1-23 or the
method of claim 24 or claim 25, wherein the composition has a steviol glycoside
composition enriched for RebD or RebM relative to the steviol glycoside composition of a
wild-type Stevia plant.




















